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CHAPTER! 
INTRODUCTION 
Background 
Osteoarthritis (OA) is the most common joint disorder and its etiology is 
relatively unknown. It currently affects more than 20 million Americans. Osteoarthritis 
begins with the breakdown of cartilage of the joints, resulting in joint pain and stiffness. 
OA commonly affects the joints of fingers, knees, hips, and spine. After age 45, women 
experience a more dramatic increase in the incidence of OA than men. The gender 
difference in prevalence of OA has been linked to menopause and ovarian hormone 
deficiency. However, an alarming number of both men and women are afflicted with this 
joint disorder. The incidence of OAis greatest in the knee joint in comparison to the 
other joints involved. Although its link to sex hormones is yet undetermined, findings 
from animal studies imply that OA can be provoked by estrogen administration. 
Furthermore, recent reports indicate that estrogen is causatively related to OA in both 
men and women. The fact that OA is not always symmetrical in a given individual 
indicates that variations within the joints may be involved. 
Research Objectives 
The principal objective of this research is to elucidate if estrogen receptors (ER) 
exist in articular cartilage of male and female with and without OA. Furthermore, this 
study will determine if osteoarthritic symptoms are related to the abundance of these 
receptors and the concentration of 1713-estradiol in the synovial fluid of individuals with 
1 
OA in comparison to individuals without OA. 
The specific objectives ofthis research are as follows: 
1. To examine the presence of estrogen receptors in the knee cartilage of 
individuals with and without knee OA. 
2. To compare and contrast the estrogen levels in the knee synovial fluid of 
individuals with and without knee OA. 
3. To compare and contrast selected anabolic and catabolic markers of OA in 
synovial fluid of individuals with and without knee OA. 
Hypotheses 
The hypothesis of this study is that there is a relationship between synovial fluid 
levels of 17~-estradiol and knee OA and that cartilage from afflicted joints has higher ER 
levels than cartilage from non-afflicted joints. 
Format of Dissertation 
The research work is organized in two individual manuscript for publication. Chapter III 
and IV were written in a journal article format using the journal guidelines for Arthritis 
and Rheumatism. The other chapters follow the CBE form. 
·2 
CHAPTER II 
REVIEW OF THE LITERATURE 
Osteoarthritis 
Epidemiology and Prevalence 
Osteoarthritis (OA) is the leading cause of disability in the elderly population. In the 
United States, it afflicts 13% ofindividuals between the ages of55 and 64 and 17% of those 
65 to 74 years old (Maurer, 1979). Increasing prevalence of OA with age is further 
aggravated by the lack of treatment to reduce the overall cause of QA. It is the most common 
joint disorder, both in the U.S. and throughout the world, with relatively unknown etiology. 
Exhausting a major proportion of health care dollars, OA ranks among the top three health 
care problems of the developed world. Currently 20 million people in the U.S. are affected 
by QA and this number is predicted to exceed 59 million by the year 2020 (March, 1997). 
The relative economic impact of musculoskeletal conditions is growing rapidly with the 
passage of time, having reached 2.5% of the gross national product in 1992 (March, 1997). 
The prevalence is higher in men than in women up to approximately age 45, however, after 
age 45 the reverse is true. In addition, after age 45, women experience a more dramatic 
increase in the incidence of OA in comparison with men (March, 1997). The epidemiologic 
definition ofOA encompasses symptoms, disability, and structural changes associated with 
this disorder. Epidemiological data focus not only on the structural disease but also 
characterizes the radio graphical definition with the presence and absence of symptoms. The 
most widely used system for grading the severity of the radio graph is known as the Kellgren-
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Lawrence grading system (K.ellgren and Lawrence, 1963). This grading defines the degree of 
osteophyte formation from Oto 4 but is unclear on the issue of grading the knee with joint 
space narrowing without the presence of osteophytes. 
Incidence of Osteoarthritis 
Reports on the percentage of people who have been diagnosed with osteoarthritis 
based on medical history, examination, or radiographic evaluation confirm a striking 
increase in the prevalence ofOA of the hand, foot, knee, and hip joints with increasing age 
(Felson et al., 1995; Lawrence et al., 1998). In the Framingham study population, it was 
found that the percentage of people who have mild, moderate, or severe radiographic 
changes indicative of osteoarthritis in at least one joint increases progressively from less than 
5% in individuals younger than 25 years of age to more than 80% in individuals more than 
75 years of age (Felson et al., 1987; Anderson and Felson, 1988). More specifically, those 
with moderate or severe radiographic changes in relation to OA in at least one joint increases 
dramatically from 5% in individuals younger than45 years of age to 40% in those 75 years 
and older (Lawrence et al., 1996). Regardless of the relationship between age and OA, the 
widespread view is that osteoarthritis results from normal wear and tear. The resulting 
stiffness of joints of almost everyone who lives past the age of 65 and the association 
between joint use, aging, and joint destruction remains uncertain (Cooper et al., 1996; 
Lawrence et al., 1998). 
Unlike the joint destruction seen in other rheumatic joint diseases with major 
systemic inflammatory components such as rheumatoid arthritis (RA), OA consists of a 
regressive sequence of changes in the cells and matrix that results in the loss of structure and 
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function of articular cartilage accompanied by attempts at cartilage repair and the remodeling 
of underlying bones (Grynpas et al., 1991; Dequeker et al., 1997). Because of these repair 
and remodeling processes, the degeneration of the articular surface in OA is not uniformly 
progressive, and the rate of degeneration varies among individuals and among joints 
(Buckwalter and Lane, 1996; Buckwalter and Lane, 1997). On occasions, this degeneration 
may occur rapidly, but in most joints it progresses slowly over many years. However, in 
some cases, this process may . stabilize or even decrease spontaneously with partial 
restoration of the articular surface and a resulting decrease in symptoms. 
Primary and Secondary Osteoarthritis 
Primary or idiopathic osteoarthritis is the degeneration of articular cartilage and 
alterations in single or multiple joints due primarily to aging and wear and tear of the tissue. 
This results in the loss of structure and function of the articular cartilage causing pain and 
loss of motion (Buckwalter and Martin, 1995). In an increasing number ofindividuals, OA is 
classified as secondary on the basis that the joint degeneration is mainly as a result of 
traumatic joint injury or from developmental, metabolic, and systemic disorders which 
destroy the articular surface (Buckwalter and Martin, 1995). This generally progressive loss 
of articular cartilage is accompanied by attempted repair of the cartilage, remodeling and 
sclerosis of the underlying subchondral bone, and in many cases the formation ofbone cysts 
and marginal osteophytes. The diagnosis of OA requires the presence of symptoms and signs 
that may include; joint pain, restriction of motion, crepitus with motion,joint effusions, and 
deformity (Kuettner and Goldberg, 1995). Although OA is most prevalent in the foot, knee, 
hip, spine, and hand joints (Altman et al., 1986; Altman et al., 1990; Altman et al., 1991), it 
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can affect any synovialjoint as well. 
Osteoarthritis develops most frequently in the absence of a known cause (primary 
OA) and less often it develops as a result of a joint injury, infection or one of a variety of 
hereditary, developmental, metabolic and neurologic disorders (secondary OA). The age of 
onset associated with secondary OA depends on the underlying cause, thus, it may develop 
in young adults and even children as well as the elderly (Mitchell and Curress, 1977). In 
contrast, there is a strong associatio.n between the prevalence of primary osteoarthritis and 
increasing age. The tools to assess the prevalence of osteoarthritis have numerous 
limitations, including difficulty in defining and establishing the diagnosis and in evaluating 
more than a few synovialjoints in each individual (Altman et al., 1986; Altman et al., 1990; 
Altman et al., 1991). 
Biology of Articular Cartilage 
Composition of Cartilage 
Articular cartilage appears histologically to be a simple inert tissue and has a firm 
slick surface that resists deformation (Buckwalter et al., 1988). Under the light microscope, 
the articular cartilage consists primarily of extracellular matrix, with only one type of cell, 
known as chondrocytes. Cartilage is a non-vascular tissue as it lacks blood vessels, 
lymphatic vessels, and nerves. In comparison with tissues such as muscle and bone, it has a 
low level of metabolic activity and appears to be less responsive to changes in loading or to 
injury (Buckwalter et al., 1988; Buckwalter et al., 1990). The morphology of articular 
cartilage shows that it has a highly intricate and ordered structure and that a variety of 
complex interactions between the chondrocytes and the protein matrix actively maintain the 
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integrity of the tissue. The articular cartilage is composed of cells, water, and a matrix 
macromolecular framework, and it is this framework that provides the cartilage its 
mechanical properties (Buckwalter et al., 1990). The cells of the cartilage make up the 
smallest part of the total volume of cartilage (Stockwell, 1967). 
Chondrocytes 
Within the articular cartilage, there is only one specialized type of cell known as 
chondrocyte (Stockwell, 1978; Buckwalter et al., 1988). Chondrocytes from different 
locations of the articular cartilage differ in size, shape and activity (Aydelotte et al., 1992). 
These cells contain organelles necessary for matrix synthesis and in some cases have short 
cilia extensions, which may play a role in sensing mechanical changes in the matrix. 
Chondrocytes are surrounded by extracellular matrix and do not form cell-to-cell contacts. 
These cells in their mature stage are spheroidal in shape and synthesize type II collagen, 
large aggregrating proteoglycan, and specific non-collagenous proteins to form cartilaginous 
matrix (Aydelotte et al., 1992; Aydelotte et al., 1996). Individual chondrocytes are quite 
active metabolically but the total activity of the cartilage tissue is quite low due to the low 
cell density (Stockwell, 1978; Aydelotte et al., 1996). 
In relation to the mechano-structural properties of the articular cartilage, 
chondrocytes appear to remain unchanged in location, appearance, and activity. The type of 
macromolecules that form the matrix and the concentration of water are important to the 
structural response of this tissue (Mow and Rosenwasser, 1988). Maintenance of the articular 
surface requires turnover of the matrix macromolecules, which involves the continuous 
replacement of degraded matrix components and alteration in the macromolecular 
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framework of the matrix in response to the use of the joint (Mow and Rosenwasser, 1988). 
To achieve these activities, the chondrocytes must sense the changes in the matrix due to 
degradation as well as changes in macromolecules in relation to the demands placed on the 
articular surface (Athanasiou et al., 1991). The cells respond by synthesizing appropriate 
types and amounts of the macromolecules (Buckwalter et al., 1990). 
Cartilage Metabolism 
The chondrocytes derive their nutrients from the synovial fluid through diffusion via 
a double barrier, first in the synovial tissue and then the cartilage matrix. The matrix barrier 
is restrictive in respect to not only the size of the materials but also with respect to their 
charge (Mourades, 1973). The barrier system results in low concentration of oxygen for the 
chondrocytes in relation to most other tissue, therefore, these cells depend primarily on 
anaerobic metabolism (Mourades and Schneiderman, 1987; Fischer et al., 1995). The activity 
of the chondrocytes varies during different stages of skeletal growth. In growing individuals 
they produce new tissue to expand and model the .articular cartilage surface (Fischer et al., 
1995). In skeletal maturity, the chondrocytes do little to change the volume of the tissue, but 
mainly replenish the degraded macromolecules and minimal remodeling of the articular 
surface (Buckwalter et al., 1994; Buckwalter and Lane, 1996). Also, the rate of metabolic 
activity and matrix synthesis declines. After completion of skeletal growth, chondrocytes do 
not undergo further cell division, but rather continue to synthesize collagens, proteoglycans 
and non-collagenous proteins (Buckwalter et al., 1993; Buckwalter and Lane, 1996). 
Enzymes produced by the chondrocytes are responsible for degradation of the matrix 
macromolecules. The presence of the fragmented matrix molecules increases the synthesis 
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activity of chondrocytes to replace the matrix framework (Buckwalter, 1995; Gueme et al., 
1995). Other factors, which may influence the balance in the synthetic and degradative 
activities, include frequency and intensity of the joint loading. Immobilization of the joint or 
a marked decrease in joint loading alters chondrocyte activity so that degradation of cartilage 
exceeds synthesis (Buckwalter, 1995). With aging, the capacity of the cells to synthesize the 
proteoglycans and their response to other stimuli such as growth factors decreases (Gueme et 
al., 1995; Martin and Buckwalter, 1996). These age-related changes may limit the ability of 
the cells to maintain the tissue and thereby contribute to the degeneration of the articular 
cartilage (Martin and Buckwalter, 1996). 
Matrix and Collagen Framework 
The matrix of the articular cartilage is made up of tissue fluid and the framework of 
structural macromolecules, which includes proteoglycans, collagens and non-collagenous 
proteins, that give the tissue its form and stability. The interaction of these two components 
gives the tissue its mechanical properties of stiffness and resilience (Buckwalter and Mow, 
2001 ). Water contributes as much as 80% of the wet weight of articular cartilage, and the 
interaction of the water with the matrix macromolecules substantially influences the 
mechanical properties of the tissue (Mankin, 1978; Maroudas and Schneiderman, 1987; Lai 
et al., 1981 ). The tissue fluid contains small proteins, metabolites, and a high concentration 
of cations to balance the negatively charged proteoglycans. The structural macromolecules of 
the cartilage, collagens, proteoglycans, and non-collagenous proteins, contribute 20% to 40% 
of the wet weight of the tissue (Buckwalter et al., 1990; Martin and Buckwalter, 2000). 
These individual components which make up the macromolecule framework differ in their 
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concentrations within the tissue and in their contributions to the tissue properties. Collagen 
makes up about 60% of the dry weight, proteoglycans contribute about 25 to 35%, andnon-
collagenous proteins and glycoproteins 15% to 20%. Collagen is distributed relatively 
uniformly throughout the depth of the cartilage, and its meshwork gives cartilage its form 
and tensile strength (Buckwalter and Mow, 2001). Proteoglycans and non-collagenous 
proteins bind to the collagen meshwork and become mechanically entrapped within it. Some 
of the non-collagenous proteins assist in organization and stabilization of the 
macromolecular framework while others help the chondrocytes to bind to the 
macromolecules of the matrix. 
Articular cartilage contains multiple genetically distinct collagen types and the 
organization of these throughout the tissue provides tensile stiffness and strength (Bruckner 
et al., 1988; Hardingham et al., 1992). These fibrils also contribute to the cohesiveness of the 
tissue by mechanically entrapping the large proteoglycans. The principal collagen, Type II, 
accounts for 90 to 95% of the collagen in articular cartilage and is the primary component of 
the cross-banded fibrils strength (Bruckner et al., 1988; Hardingham et al., 1992; Hagiwara 
et al., 1993). Proteoglycans consist of a protein core and one or more glycosaminoglycan 
chains (long-unbranched polysaccharide) (Hardingham et al., 1992; Roughley and Lee, 
1994). Glycosaminoglycans found in cartilage include hyaluronic acid, chondroitin sulfate, 
keratan sulfate, and dermatan sulfate. The concentration of these molecules varies among 
sites within the articular cartilage and also with age, injury to the cartilage, and disease. 
Articular cartilage contains two major types ofproteoglycans known as large aggregating 
monomers or aggrecans and small proteoglycans including decorin, biglycan, and 
fibromodulin (Hardingham et al., 1992; Roughley and Lee, 1994). Link proteins stabilize 
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the association between the monomers and hyaluronic acid and appear to have a role in 
directing the assembly of aggregates (Hardingham et al., 1992). The formation of aggregates 
helps to anchor the proteoglycans within the matrix and prevent their displacement during 
the deformation of the tissue (Hardingham et al., 1992; Roughley and Lee, 1994). This helps 
to stabilize and organize the relationship between proteoglycans and the collagen meshwork. 
The non-collagenous proteins and glycoproteins are not very well studied for their role in 
relation to proteoglycans and collagen (Roughley and Lee, 1994). Anchorin CII, a collagen 
binding chondrocyte surface protein helps in anchoring chondrocytes to the collagen fibers 
of the matrix (Rosenberg, 1992). Cartilage oligomeric protein (COMP), an acidic protein, is 
concentrated primarily within the matrix of the chondrocyte and allows for binding between 
the cells and the matrix (Rosenberg, 1992; Marcelino and McDevitt, 1995). This molecule 
also serves as a good marker of cartilage turnover in progression of cartilage degeneration in 
patients with osteoarthritis (OA). Other non-collagenous matrix proteins such as fibronectin 
and tenascin also function in matrix organization and cell-matrix interactions. The response 
of these molecules is also altered in conditions such as OA (Rosenberg and Buckwalter, 
1986). 
Structural Organization of Cartilage 
The primary function of the chondrocytes is to synthesize and organize collagens, 
proteoglycans and the non-collagenous proteins into unique and highly ordered matrix 
structure to form articular cartilage (Buckwalter et al., 1990; Mankin et al., 1994). The 
composition, organization, and mechanical properties of this matrix as well as the 
chondrocyte morphology and function vary according to the depth of the articular surface. 
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These changes are identified in layers called zones and there are four zones known as 
superficial, transitional, middle (radial), and a zone of calcified cartilage (Buckwalter et al., 
1988; Poole, 1997). The zones differ in respect to their concentration of water, proteoglycan, 
and collagen including the size of the aggregates. Cells in these zones also differ in size, 
shape, and orientation relative to the articular surface (Buckwalter et al., 1988). This also 
causes a variation in the degree of metabolic activity between the zones. Chondrocytes 
respond differently to mechanical loading which suggests that the development and 
maintenance of articular cartilage under normal conditions depends partly on the 
differentiation of the distinct populations of these cells across the zones (Buckwalter et al., 
1990; Guilak et al., 1997). 
Matrix Compartments 
The variations in the matrix within the structural zones are distinctly categorized into 
three compartments or regions called pericellular, territorial, and interterritorial (Buckwalter 
et al., 1988; Poole, 1997). The pericellular and territorial regions serve the needs of the 
chondrocytes in relation to their binding of the matrix macromolecules and protecting the 
cells from damage during the loading and deformation of the tissue (Guilak et al., 1997). 
These regions also serve to transmit mechanical signals to the chondrocytes when the matrix 
deforms during joint loading. The interterritorial matrix provides the mechanical properties 
of the tissue (Buckwalter et al., 1988; Poole, 1997). 
The interdependence of the chondrocytes and the matrix makes the lifetime 
maintenance of the cartilage tissue possible and this does not end when the cells secrete the 
matrix macromolecules (Mankin et al., 1994; Simkin and Bassett, 1995).Thematrixprotects 
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the chondrocytes from mechanical damage during normal use of the joint by helping to 
maintain their shape and phenotype (Treadwell and Mankin, 1986; Keuttner et al., 1991). 
Nutrients, substrates for the synthesis of matrix molecules, degraded matrix molecules, 
newly synthesized molecules, metabolic waste products, and molecules that help regulate 
cell function all pass through the matrix and in some instances are stored within the matrix 
(Levick and McDonald, 1995). The type of molecules and the rate at which they can pass 
through the matrix depends on the composition and the organization of the matrix, especially 
that of the large proteoglycan molecules (Levick and McDonald, 1995). 
Changes in the Diseased Joint 
Morphological Changes 
Osteoarthritis involves all of the tissues. that form the synovial joint, including 
articular cartilage, subchondral and metaphyseal bone, synovial tissue and ligaments, joint 
capsule, and muscles that surround the joint (Sokoloff, 1987). However, the primary changes 
consist of loss of articular cartilage, remodeling of subchondral bone, and formation of 
osteophytes (Mitrovic and Riera, 1992; Poole et al., 1995). The earliest histological changes 
in OA include the superficial zone of the articular cartilage and extend into the transitional 
zone (Radin and Rose, 1986; Clark and Huber, 1990). There is decreased staining for 
proteoglycans in these regions and protrusion of blood vessels from subchondral bone as a 
result of increased remodeling (Heingegard et al., 1987). Investigators suggest that the 
stiffening of subchondral bone due to this remodeling causes the degeneration of articular 
cartilage (Radin and Rose, 1986). Alternatively, the loss of articular cartilage could increase 
the level of mechanical stress on the underlying bone, causing aggressive bone remodeling to 
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occur (Radin and Rose, 1986). However, it is not certain as to what is the correct order of 
these events. But in most instances, the degeneration of articular cartilage and the remodeling 
of subchondral bone are both present when symptoms develop and it is this loss of cartilage 
that leads to the direct loss of joint function. 
Stages of Joint Degradation 
Many of the mechanisms responsible for the progressive loss of cartilage in 
degenerative joint disease remain unknown. However, this process can be divided into three 
overlapping stages which include disruption or alteration of the cartilage matrix, the 
chondrocyte response to tissue damage, and the decline of the chondrocytic response to 
restore or maintain tissue leading to loss of articular cartilage (Martin and Buckwalter, 1996; 
Poole, 1997). The first stage is when there is an overall disruption of the matrix framework 
and an associated increase in the concentration of water (Poole, 1997). The collagen 
meshwork may also be damaged and the degree of proteoglycan aggregation decreases 
(Martin and Buckwalter, 1996). These changes proceed to the response of the chondrocytes 
in the second stage by increasing synthesis and decreasing the degradation of the matrix. 
Rate of degradation is controlled by the balance in activity between both anabolic and 
catabolic growth factors and cytokines (Poole et al., 1995). 
In this second stage of the development ofOA, the repair mechanisms may increase 
the synthesis of matrix macromolecules and to a lesser extent cell proliferation which can 
counter the catabolic effects and stabilize or in some instances restore the tissue (Martin and 
Buckwalter, 1996). This repair response may continue for years and in some individuals 
reverse the course of osteoarthritis at least temporarily. The failure to stabilize or restore the 
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tissue leads to the third stage in the development of OA (Poole, 1997). In the third stage, 
there is a progressive loss of articular cartilage as well as a notable decline in the anabolic 
response of the chondrocytes (Setton et al., 1999). This decline can result from mechanical 
insults and chondrocyte death which no longer can be supported by a stable and functional 
matrix (Martin and Buckwalter, 1996). There is also a down-regulation of the chondrocytic 
response to anabolic growth factors and cytokines and an increase in synthesis and 
accumulation of molecules in the matrix such as catabolic cytokines and growth factor-
binding proteins which decrease the overall anabolic effect (Setton et al., 1999). The loss of 
articular cartilage leads to the symptoms of pain and joint dysfunction associated with OA. 
This loss occurs most frequently with increasing age, possibly because age related changes in 
the cartilage matrix and the decrease in the chondrocytic anabolic response compromise the 
ability of the tissue to maintain and restore itself (Martin and Buckwalter, 1996). 
Osteoarthritic Bone 
The alteration in the subchondral bone that accompanies the degeneration of articular 
cartilage includes increase in bone density of the subchondral bone (Milgram, 1983; 
Dequeker et al., 1997). This includes the formation of cyst-like bone cavities containing 
fibrous and cartilaginous tissue and the appearance of regenerating cartilage within and on 
the subchondral bone surface (Amir et al., 1992; Oegema et al., 1997). This occurs more 
frequently on the periphery of the joint, where osseous and cartilaginous bulges known as 
osteophytes can sometimes form (Altman et al., 1986; Pottenger et al., 1990). The increase in 
bone density of the subchondral bone results from the formation of abnormal bone on 
existing trabeculae and is the usual first sign of the degenerative joint disease (Milgram, 
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1983). At the end stage of the disease, the articular cartilage has been completely lost, 
leaving thickened dense subchondral bone articulated with a denuded osseous surface 
(Migram, 1983; Kamibayashi et al., 1995). The bone remodeling combined with the loss of 
articular cartilage changes the shape of the joint and can lead to shortening of the involved 
limb, deformity, and instability. 
Formation of Osteophytes 
In most synovialjoints, growth ofosteophytes accompanies the changes in articular 
cartilage and in the subchondral and metaphyseal bone. Osteophytes have a cartilaginous 
surface that closely resembles normal articular cartilage and that makes them appear to be an 
extension of the joint surface (Pottenger et al., 1990). They are usually palpable and may 
appear to be tender and in all joints they can restrict motion and contribute to pain with 
motion. Osteophytes represent a response to the degeneration of articular cartilage and the 
remodeling of subchondral bone, including the release of anabolic cytokines that stimulate 
cell proliferation and the formation of osseous and cartilaginous matrices (Poole et al., 1993; 
Matyas et al., 1997). The loss of articular cartilage also leads to secondary changes in the 
synovial tissue where the synovial membrane often has a mild-to-moderate inflammation 
reaction and may contain fragments of articular cartilage (Poole et al., 1993). With time, the 
ligaments and the muscles become contracted causing decreased use of the joint and a 
decreased range of motion leading to muscle atrophy. These changes often contribute to the 
stiffness and weakness associated with OA (Poole et al., 1993). 
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Abnormal Loading Causes Degeneration 
Despite the importance of regular activity for maintenance of the joint, some types of 
repetitive joint use can accelerate the development of degenerative joint disease (Buckwalter, 
1995). Studies of individuals who have physically demanding occupations have shown that 
repetitive, intense joint loading may lead to early joint degradation (Buckwalter et al., 1993; 
Buckwalter and Lane, 1997). Specific activities that have been associated with osteoarthritis 
include repetitive lifting or carrying of heavy objects, awkward work postures and 
continuously repeated movements. Participation in sports or other activities that repeatedly 
expose joints to high levels of impact also may increase the probability of joint destruction 
(Lane, 1995; Buckwalter and Lane, 1996). 
Individuals who have an abnormal anatomy or function of the joint including 
dysplasia, malalignment, instability, disturbances in the innervation of the joint muscles, and 
inadequate muscle strength or endurance, probably have a greater risk of degenerative joint 
disease (Buckwalter, 1995; Fisher and Pendergast, 1997; Hurley, 1999). Subjecting the joints 
to loading greater than those that result from normal activities of daily living can presumably 
increase the risk even further. These individuals as well as those who have early OA require 
regular exercise, but should have a detailed evaluation of their joint structure and function 
before initiating such an exercise regimen. In most instances, exercise programs that 
maintain joint motion and muscle strength withminimal loading should be selected (Leviseth 
et al., 1989; Minor et al., 1989; Schilke et al., 1996; Suomi and Lindauer, 1997). 
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Osteoarthritis of the Knee 
Incidence and Gender Differences 
Epidemiologic surveys have suggested sex-associated differences related to age and 
disease severity (Wilson et al., 1990; Oliveria et al., 1995; Nevitt et al., 1998). Among 
individuals older than 50 years of age, women appear to be affected with greater severity, 
and with more joints involved per female patient in comparison with men. The knee joint is 
one of the more commonly afflicted joints in OA (Felson, 1988). Of all of the joints 
involved, there is definitive evidence of knee OA present in 60% to 70% of the afflicted 
individuals in their seventh and eight decade of life (Bagge et al., 1992a; Bagge et al., 
1992b). Sex differences have consistently been observed in knee OA, with an excess 
prevalence in women with age. Kellgren and Lawrence (Kellgren and Lawrence, 1957) 
found that persons with generalized OA often had involvement of the knee joint as well. In 
the Framingham study, 2% of the women versus 1.4% of the men developed radiographic 
knee OA per year (Felson et al., 1995). Another study which evaluated the incidence of 
symptomatic OA of the hand, hip and knee reported higher rates in women in comparision to 
men (Oliveria et al., 1995). A study by Wilson and colleagues in a Northern European 
county indicated that the incidence of symptomatic OA was equal in women and men but the 
age-adjusted rates between the gender varied where the incidence is greater in women 
compared to men (Wilson et al., 1990). 
Pathogenesis, Clinical Features, and Risk Factors 
Osteoarthritis is generally viewed as a degenerative disorder involving cartilage 
degradation in aging (Rosenberg et al., 1992). Typically, the degenerative changes are 
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accompanied by a local inflammatory component that may accelerate joint destruction 
(Ismaiel et al., 1992). Hyaline articular cartilage is made up of a matrix of type II collagen 
fibers and proteoglycans, as well as the chondrocytes that produce the matrix, and water 
(Kraus, 1997). In OA the proteoglycan content of the cartilage is gradually depleted, leading 
to an initial increase in water content and a loss of compressibility and shock absorption, and 
culminating in fibrillation and breakdown (Kraus, 1997). 
The main clinical features of OA are pain, stiffness, loss of function, and ultimately 
joint deformity (March, 1997). Any of the joints may be affected in isolation or as part of 
primary generalized OA. The most common joints involved in OA include those of the knee, 
hands, feet, hips, and the apophyseal joints of the spine. OA is primarily a disorder of the 
hyaline articular cartilage that coats the bony surface of all synovialjoints and the meniscus 
(Dequeker, 1985). 
In addition to age, a number of other factors have been suggested as risk factors for 
the development of OA including: genetics, obesity, joint hypermobility, joint trauma, 
immobilization, peripheral neuropathy, crystals in joint fluid or cartilage, and repetitive joint 
overuse (Dequeker, 1985). The pathological processes and the radiological features vary to 
some degree across the different joints. Therefore, OA is generally considered to be a 
heterogeneous disorder and no two joints may be afflicted equally in the same individual. 
Predominance of generalized OA in women suggests that changes in production and nature 
of estrogens may be risk factors in the development ofOA. 
Osteoarthritis and Bone Fractures 
There is an inverse relationship between the incidence of osteoarthritis and 
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osteoporosis. This suggests that high periarticular bone mass may be detrimental to cartilage 
integrity and increase the risk ofOA (Radin et al., 1972). Cross sectional studies (Hannan et 
al., 1993, Hart et al., 1994, and Nevitt et al., 1995) have established an increased prevalence 
of radiographic knee and hip OA in the presence of osteophytes and increased bone mineral 
density (BMD). Prospective study found a positive relationship between higher bone 
densities and increased risk of knee OA in older women (Zhang et al., 2000). However 
amongst women in this study who already had knee OA, those that had a low BMD and were 
losing bone faster had a more rapid progression of knee OA compared to those who had high 
BMD and were losing bone more slowly (Zhang et al., 2000). Overall, individuals with knee 
and hip OA appear to have an increased rate of bone loss (Jones et al., 1995; Burger et al., 
1996; Arden et al., 1999) which can contribute to increased risk of fracture. However, not all 
of the increased fractures can be attributed to bone loss because individuals with joint 
dysfunction and hypermobility have a greater risk of experiencing a fall. 
In a cohort of white women, Hart and colleagues (2002) found that lumbar spine and 
hip BMD measured at baseline were significantly higher in women who subsequently 
developed knee osteophytes. The higher BMD was only associated with knee osteophytes 
and not with joint space narrowing (Hart et al., 2002). During the follow-up period, subjects 
from this study who sustained a fracture had a 70% lower risk of developing knee 
osteophytes. From the clinical perspective, knee osteophytes are an important radiographic 
measure of early knee OA and are strongly suggestive of knee pain and progression of the 
degenerative condition (Hart et al., 2002; Lane and Nevitt, 2002). Lack of measurement 
techniques has limited the data on the relationship between the bone changes associated with 
OA and the incidence of fracture. 
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Proposed Role of Estrogen in Osteoarthritis 
Epidemiologic studies have indicated that women over the age of 50 are the most 
vulnerable to joint disorders, especially OA. Sex hormones may play a role in the 
development ofOA in women (Spector and Campion, 1989; Felson and Nevitt, 1998). The 
prevalence of OA increases in women following menopause and rises faster with age in 
women theninmen(Van Saase et al., 1989; Oliveria et al., 1995). Tsai and colleagues (Tsai 
et al., 1992a) have suggested that excessive levels of synovial fluid estrogen are responsible 
for the development of OA in humans. In some animal studies, when estrogen was 
administered directly to the knee joint, it resulted in an increased frequency and severity of 
OA (Rosner et al., 1986, Tsai and Lui, 1992b). Furthermore, Tsai and Lui (1992b) have 
shown that intraarticular injections of estradiol to ovariectomized rabbits induced an up-
regulation of estrogen receptors in condylar cartilage at an early stage of OA and cartilage 
degeneration and erosion at the late stage. In OA, looser matrix might be synthesized in the 
medial compartment, allowing molecules in the synovial fluid, including estrogens to be 
taken up by the chondrocytes, and therefore resulting in cell death and cartilage erosion (Tsai 
and Lui; 1992b ). Estrogen may affect articular cartilage by modulating the synthesis of the 
cartilage matrix and the production of matrix enzymes (Rosner et al., 1982). Estrogen 
receptors are found in articular cartilage (Ushiyama et al., 1999), but estrogen may also 
influence cartilage metabolism via cytokines (Pelletier et al., 1993). Estrogen has also been 
suggested to influence the development of OA through its effects on bone metabolism 
(Healey et al., 1985; Burger et al., 1996; Dequeker et al., 1996). 
In partially menisectomized rabbits, estrogen accentuates the frequency and severity 
of OA. Estradiol also modulated articular cartilage metabolism by suppression of DNA and 
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proteoglycan synthesis (Rosner et al., 1982). Furthermore, intraarticular injection of estradiol 
to the knee joint impaired lactate dehydrogenase resulting in an overall disruption of matrix 
collagen (Rosner et al., 1982; Rosner et al., 1992) in cartilage tissue. These observations 
imply that the estrogen can affect chondrocyte metabolism and proliferation, possibly 
through a receptor-mediated mechanism (Rosner et al., 1992). 
There are a number of epidemiological studies that have examined the possible 
relationship between estrogen replacement therapy (ERT) and risk of OA. Several 
investigators reported that women who at one time have been on ERT have a lower than 
expected risk of knee or hip OA (Hannan et al., 1990; Samanta et al., 1993; Nevitt et al., 
1996; Spector et al., 1997; Vingard et al., 1997). Prospective cohort investigation of the 
Framingham study indicated that the use of ERT had a moderate protective effect against 
worsening of radiographic knee OA among elderly women (Zhang et al., 1998). Although 
evidence from these studies may suggest that estrogen protects against OA, there are 
important limitations to be considered. Women on ERT tend to be generally healthier, 
thinner and more active, as well as better educated than non-users. These characteristics as 
well others may benefit the estrogen users and make them less prediposed to have OA than 
the non:-users. Currently there are no published clinical trials on ERT in OA. Longitudinal 
studies are needed in which estrogen users and non-users can be followed and carefully 
characterized for OA. 
Estrogen may also play an important role in male OA. Higher synovial estradiol and 
higher estrogen receptor levels in cartilage of individuals with OA compared to non-OA may 
be primary reasons for the incidence of OA in males as well (Tsai et al., 1992a; Ushiyama et 
al., 1999). The negative effects of estradiol in synovial fluid may be counterbalanced by 
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endogenous testosterone, resulting in a lower estrogen/testosterone ratio or a lower 
unopposed, free estradiol to interact with cartilage. 
Estrogen Receptors and Selective Estrogen Receptor Modulators 
Estrogen Receptors 
Estrogen has been shown to act genomically by coupling with the estrogen 
receptor and its coactivators to induce changes in gene expression. 17B-estradiol (E2) and 
the estrogen receptors have been shown to form a ligand-estrogen receptor complex. 
There are two distinct pathways by which E2 exerts its effects. In the "classical" pathway, 
the ligand estrogen receptor complex dimerizes and interacts with the estrogen response 
element (ERE), a specific sequence within the DNA (Paech et al., 1997). The ligand-
estrogen receptor complex has two transactivation domains (AF-1 and AF-2) that will 
bind to various proteins and initiate transcription of the estrogen-dependent gene. In the 
"nonclassical" pathway, the ligand-estrogen complex does not bind directly to the DNA, 
but instead, it interacts with an AP-1 response element by binding to coactivator proteins 
known as fos and jun (Paech et al., 1997). Coactivator proteins will either recruit proteins 
that are directly involved in transcription or that will facilitate the process of RNA 
transcription (Paech et al., 1997) Estrogen can also bind to steroid hormone receptors and 
activates proteins known as corepressors (Shibata et al., 1997). Corepressors are thought 
to silence transcription, though the mechanisms are not completely understood (Shibata et 
al., 1997) 
The challenge in understanding the mechanisms by which estrogen exerts its 
effects is due to the existence of its two receptor subtypes, estrogen receptor (ER)-a and 
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ERP. The two receptors share considerable homology but differ in the C-terminal ligand 
binding domain and its N-terminal transactivation domain (Kuiper et al., 1998). Paech 
and colleagues (1997) have demonstrated that the transcriptional effects elicited by E2 are 
determined by whether or not it interacts with ERa or ERP. Through non-classical 
binding, transcription is activated by estrogen at ERa and inhibited through ERP. The 
two receptors also exhibit different responses to drugs such as tamoxifen and raloxifene 
which are categorized as either anti-estrogens or selective estrogen receptor modulators 
(SERM). While estrogen induces negative transcription regulation, SERM induce 
positive regulatory sequences when interacting with ERP. This may explain, in part, how 
SERM are able to induce beneficial estrogenic effects on bone and cardiovascular 
without dramatically increasing the risk of cancer of the reproductive organs. 
Tissue Specific Actions of SERM 
The levels of expression for each ER subtype vary from organ to organ, and bind 
estrogen with varying affinity. The ratio ofERa to ERP in different vascular beds vary 
and this may explain the different responses exerted by SERM in various tissues (Kuiper 
et al., 1997). The two well known SERM, tamoxifen and raloxifene, are non-steroidal 
phenylethylene derivatives that have been shown to bind to ERP with higher affinity than 
ERa (Gustaffson, 1998). In some cases, SERM mimic the effects of estrogen, while in 
other cases, antiestrogenic effects are observed (Gustaffson, 1998). They were first 
characterized as antagonists/partial agonists on the basis of their binding to ERa. 
However since then they have been shown to act as full estrogen agonists in bone through 
their interaction with ERp. The differential estrogenic effects of SERM vary, as 
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tamoxifen has been shown to have estrogenic actions in the uterus, while raloxifene does 
not (Gustaffson, 1998). Thus the acronym SERM takes into account the selective 
modulations of the ER in specific tissues (Gustaffson, 1998). The selective action of both 
natural and synthetic SERM and their interaction with each of the ER subtype across 
different tissues needs to be further investigated. 
Role of Cytokines and Growth Factors in OA 
Function 
Cytokines and growth factors are released by cells in response to specific signals and 
influence the function of target cells by exerting a positive or negative effect on gene 
expression (Nathan and Sporn, 1991). Because they have a relatively short half-life, they 
usually exert their influence on cells in the local environment. Cytokine production and its 
effects on target cells are regulated in several ways. Homeostasis is maintained as a balance 
between a particular cytokine and various naturally occurring molecules that function as 
cytokine inhibitors (Nathan and Sporn, 1991). Cellular mechanisms which influence this 
regulation include: 1) specific receptor antagonists competing with ligand for receptor 
binding site to prevent signal transduction; 2) autoantibodies which bind to the ligand and 
neutralize it before it reaches the receptor; and 3) proteolytic cleavage of the extracellular 
portion of the receptor (Arend and Dayer, 1993). These control mechanisms are essential for 
maintaining tissue integrity. Alterations in the balance of any of these mechanisms may 
contribute to destructive processes within the joint. However the complexity of the 
interactions within cytokines and growth factors makes the unraveling of pathways involved 
in joint destruction a formidable task (Stockwell, 1993). 
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The cartilage tissue is maintained by the equilibrium between the effects of catabolic 
cytokines (e.g. IL-la and p, tumor necrosis factor-a) which induce the production of 
specific matrix degrading metalloproteases, and anabolic growth factors such as insulin-like 
growth factor and transforming growth factor-P which induce the production of building 
blocks of cartilage such as collagen and proteoglycans (Dayer and Fenner, 1992). 
In osteoarthritis, which is the most common type of arthritis, the breakdown of the 
joint tissue occurs in several phases (Ismaiel et al., 1992). This depletion suggests an overall 
failure in the cytokine-controlled matrix homeostasis, with a shift in equilibrium between 
synthesis and degradation favoring catabolic processes. In the earlier stages of OA, the 
chondrocytes attempt to repair the cartilage by increasing the synthesis of matrix 
macromolecules (Trippel, 1995). The increased presence of anabolic growth factors 
presumably activates the chondrocytes to stimulate the matrix synthesis. However, 
compositional change in the matrix molecules may interfere with this process by reduicng 
their capacity to aggregrate properly with hyaluronic acid (Mankin et al., 1971 ). Over time, 
the matrix losses its resiliency and fails to withstand the mechanical stress placed on the 
joints. In the later stages of the disease process, enhanced cartilage degradation far exceeds 
the ability of the chondrocytes to synthesize new matrix. Furthermore, there is increased 
presence of catabolic cytokines such as IL-1 p and TNF-a that potentiate the expression of 
matrix metalloproteinases causing proteolysis of the cartilage matrix (Trippel, 1995). These 
factors can also inhibit cartilage matrix biosynthesis (Goldring et al., 1986). 
Evidence is accruing to implicate cytokines in the pathogenesis of joint diseases with 
major inflammatory and autoimmune components (Brennan et al., 1989; Dayer et al., 1992). 
However the mechanisms that initiate and cause cartilage destruction in osteoarthritis remain 
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unclear. The profile for cytokines and growth factors in based on quantitative rather than 
qualitative differences as indicated by fewer cells being recruited for their production in 
osteoarthritis. This may suggest that other processes are involved in cartilage destruction, 
and that cytokines are merely indicators of the disease activity (Holt et al., 1992). However, 
the involvement of cytokines and growth factors is a topic of interest in relation to their 
function in cartilage integrity (Pelletier et al., 1991; Rickard and Gowen, 1993). 
Catabolic Cytokines 
lnterleukin-1 (IL-lP) was first identified as an inflammatory mediator capable of 
tissue damage. Its importance in cartilage metabolism appears to be a result of its ability to 
suppress the synthesis of type II collagen, the predominant form of collagen found in 
articular cartilage (Eastgate et al., 1988). Furthermore, IL-1 p is shown to stimulate synthesis 
of type I collagen, which is predominant in fibroblasts (Smith et al., 1991; Koch et al., 1992). 
The increased presence of IL-1 p and the formation of fibroblasts suppresses the ability of 
chondrocytes to synthesize new proteoglycan, a building block in cartilage formation 
(Eastgate et al., 1988). For cartilage degradation to occur, catabolic cytokines such as IL-1 p 
must act at specific receptors on the target cells (Eastgate et al., 1988; Smith et al., 1991). In 
osteoarthritis, there is increased presence and sensitivity of IL-1 p receptors to interact with 
IL-lP and trigger the joint destruction processes (Warnock et al., 1994). 
The potency for cartilage breakdown is 10-fold less in the case of tumor necrosis 
factor than for IL-1 p and the evidence for its existence within osteoarthritic joint is 
conflicting (Martel-Pelletier et al., 1990; Westcott et al., 1993). Both in rheumatoid arthritis 
and osteoarthritis, TNFa. has been detected at the cartilage-tendon junction by 
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immunohistological analysis (Miller et al, 1993). Apparently, Both IL-lP and TNFa are 
produced by the same cells under the same stimuli. However, in osteoarthritis, the two 
cytokines are not significantly correlated during active disease (Westcott et al., 1993; 
Westcott et al., 1994). 
The multifunctional cytokine, interleuk:in-6 (IL-6) is often viewed as anti-
inflammatory, although recent reports have shown high levels of IL-6 production within the 
joint in osteoarthritis (Neitfeld et al., 1990). Catabolic cytokines such as IL-lP and TNFa 
induce the production of IL-6. In articular cartilage, the presence of IL-6 mediates the 
influence ofIL-lP on inhibition ofproteoglycan synthesis through increased IL-1 receptor 
expression (Nietfeld et al., 1990). However, other studies also have suggested a relationship 
between increased proteoglycan synthesis by chondrocytes, and increased levels ofIL-6 in 
synovial fluid (Holt et al., 1992). The direct role ofIL-6 on cartilage metabolism is uncertain 
and needs to be examined. 
Leukemia inhibitory factor (LIF) has been detected in synovial fluid of patients with 
osteoarthritis in association with the inflammatory conditions (Caroll and Bell, 1993). Local 
production by cartilage cells in combination with its capability to degrade cartilage suggests 
that LIF may stimulate the loss of proteoglycan. But studies remain inconclusive in regards 
to a role ofLIF in disease conditions such as osteoarthritis (Osborne et al., 1989; Caroll and 
Bell, 1993). 
Anabolic Growth Factors 
The overall destruction of cartilage associated with osteoarthritis is caused by an 
imbalance between the catabolic cytokines and those that maintain the proliferative 
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responses of chondrocytes. These cytokines, most commonly termed as growth factors, 
stimulate matrix synthesis (Mankin et al., 1991; Moskowitz et al., 1991). 
Insulin-like growth factor-I (IGF-I) is a potent mediator of cartilage synthesis that 
reduces degradation and promotes proteoglycan synthesis even in the presence ofIL-1 p and 
TNFa (Denko et al., 1990; Moskowitz et al., 1991; Denko and Boja, 1993). Serum IGF-I 
levels are found to be low in osteoarthritis, however the intracellular levels and mRNA 
expression are high in chondrocytes (Middleton and Tyler, 1992). The circulating levels of 
IGF-I are mediated through the presence of its binding proteins (Moskowitz et al., 1991; 
Denko and Boja, 1993). In early stages of OA, cartilage synthesis is increased to 
counterbalance the rapid loss and degradation. This increased cartilage activity coincides 
with increased IGF-I levels in the synovial fluid. However, the role ofIGF-I is quite complex 
in OA and needs further investigation. 
Transforming growth factor-P (TGFP) is produced by almost all cells in the body, 
including the chondrocytes (Wahl et al., 1990). It is a powerful mitogen for cells such as 
those in cartilage and bone and reduces inflammation and stimulates cartilage matrix 
synthesis. TGFP also inhibits matrix degradation by stimulating protease inhibitor 
production, blocking collagenase and metalloprotease release, and promoting cartilage repair 
by production of collagen and fibronectin (Wahl et al., 1990). TGFP also increased general 
protein synthesis and is thought to inhibit IL-1 p mediated degradation by decreasing the IL-
1 Preceptor expression (Wahl et al, 1990). However other studies have shown that IL-lP 
production may be stimulated by TGFP and suggest that stimulation or degradation of 
cartilage occurs depending on the balance between TGFP and the presence of other cytokines 
within the joint (Wahl et al., 1990; Chu et al., 1992). 
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In Vitro Models Using Cytokines and Growth Factors 
Isolated chondrocytes have been utilized in cell culture to elucidate mechanisms by 
which cytokines and growth factors may influence cartilage metabolism. Chandrasekhar et 
al. (1994) exposed chondrocytes isolated from rabbit articular cartilage to IL-lP, IL-6, 
TNFa, TGFP orIGF-I. IL-lp, butnotIL-6 orTNFa inhibited the synthesis and secretion of 
osteonectin, a protein indicative of cartilage formation. Stimulatory growth factors such as 
TGFP and IGF-I increased the synthesis of osteonectin in culture (Chandrasekhar et al., 
1994). 
Tyler et al. (1989) have used a model system of explanted cartilage to determine the 
role ofIGF-I in promoting matrix formation. In the presence of IL-1 and TNFa, there were 
no detectable changes in the aggregating proteoglycan synthesized by the cartilage. When 
labeled proteoglycan was measured in the explant, IGF-1 alone increased the release of 
labeled proteoglycan by 50% in relation to ones with IL-1 and TNFa present. Thus, the role 
of growth factors in promoting the synthesis of cartilage proteins in the presence of catabolic 
cytokines needs to be investigated using in vivo systems. 
Using immunohistochemical analysis, Chu et al (1992) investigated the presence and 
the role of cytokines in the cartilage/pannus junction. Both catabolic (IL-1 p, IL-6, TNFa) 
and anabolic (TGFP) cytokines were found in both normal and arthritic tissue confirming 
their important role in cartilage metabolism. Presence of catabolic cytokines was higher in 
tissues from rheumatoid arthritis (RA) patients in comparison to those with OA and without 
arthritis. The difference between RA and OA in relation to presence of cytokines is not 
clearly known. 
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Release of protein fragments, such as fibronectin, from cartilage indicates increase in 
its proteoglycan content. The increased synthesis of proteoglycan may be modulated by 
growth factors. Homandberg et al (1997) investigated the role oflGF-I and TGF~ in cultured 
cartilage cells. These growth factors enhanced the synthesis rate and content of proteoglycan 
by 50-100%. However, the increase in fibronectin was accompanied by increases in 
catabolic cytokine such as IL-1, IL-6 and TNFa. Thus, the steady-state balance of cartilage 
metabolism is directly influenced by the presence of both anabolic and catabolic cytokines. 
Biochemical Markers of Cartilage Metabolism 
Serum and Synovial Fluid 
Osteoarthritis is currently diagnosed by clinical and/or radiographic criteria which 
only allow detection in fairly advanced stages of the disease (Dieppe, 1995). The inability for 
early diagnosis ofOAhindersthe clinical assessment of the changes crucial for subsequent 
development of irreversible joint damage. Reliable and sensitive methods for monitoring 
such changes would facilitate clinical investigations of key events in the pathophysiology of 
OA (Petersson IF, 1998; Saxne, 1995). 
Cartilage and bone macromolecular fragments are released in synovial fluid during 
normal tissue turnover, but changes in the release of these molecules are likely with the OA. 
Quantification of such fragments in serum and synovial fluid should provide important 
information related to disease conditions such as OA (Saxne and Heinegard, 1995). 
However, there are confounding factors which influence the levels of potential "markers" 
which need to be considered in interpreting the results of such measurements (Saxne and 
Heinegard, 1995). For instance, serum levels will not only depend on the release of these 
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markers from the cartilage and bone, but also on the elimination rate from the joint cavity. 
Furthermore, the clearance rate from blood in turn depends on uptake and degradation by the 
liver and the filtration by the kidneys (Heinegard and Saxne, 1991). 
C-Reactive Protein (CRP) as a Marker of Inflammation 
The inflammatory marker used most commonly to assess the progression of disease 
such as OA is serum CRP. This marker is increased markedly in arthritic conditions and is 
reduced by the use of anti-inflammatory drugs (Loose et al., 1993). Serum CRP 
concentrations have been demonstrated to have a low grade acute phase response in subjects 
with mild-to-moderate OA and were positively correlated with the progression of the disease 
(Spector et al., 1997). Another study also confirmed a slight but significant increase in serum 
CRP levels ranked according to disease severity (Sipe, 1995). Population studies indicated 
that CRP levels have a stronger correlation with osteophyte grade according to the Kellgren-
Lawrence scoring scale then with the narrowing of joint space (Spector et al., 1993; Hart et 
al., 1995). This lack of association between CRP levels and narrowing of joint space is 
perhaps because joint space measurement is considered a poor measure of the disease cross-
sectionally (Spector et al., 1993; Hart et al., 1995). 
Markers of Cartilage Degradation 
A matrix protein known as cartilage oligomeric matrix protein (COMP) which was 
isolated in cartilage and is relatively specific to synovial joint tissue serves as an important 
marker for cartilage turnover (Hedbom et al., 1992). Sharif et al. (1995), found serum COMP 
levels to be significantly increased in patients with knee OA who had decreased joint space 
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or required a knee surgery during a five-year follow-up. In individuals with knee pain, 
Petersson et al., (1998) had also demonstrated that serum levels of COMP were significantly 
higher in individuals with radiographic OA during a 3-year follow-up versus those who had 
normal radiographs over the same period. Conrozier and colleagues (1998) showed that 
baseline values of serum COMP correlated with joint space narrowing parameters in patients 
with hip OA over a one-year period. However, no such correlation was found by Georges et 
al. (1997) in a study when baseline COMP levels were compared arthroscopically to disease 
progression. In a group of individuals with knee pain, serum COMP levels have correlated 
positively with the extent of bone scan abnormalities (Petersson et al., 1998). One factor 
which may influence serum COMP levels is synovitis. Knee synovitis may play a role in 
progression of OA. Higher levels of serum COMP were observed in patients with faster 
progressing joint disease (Vilirn et al., 2001). 
A specific marker for cartilage metabolism that is secreted by cultured chondrocytes 
is human cartilage glycoprotein 39 (YKL-40). The name is derived from its 40 kilodalton 
molecular weight and the one-letter code for its 3-N-terminal amino acids; tyrosine, lysine, 
and leucine (Hakala et al., 1993; Hu et al., 1996). YKL-40 is synthesized by articular 
chondrocytes (Hakala et al., 1993; Hu et al., 1996) and synovial cells (Nyirkos and Golds, 
1990; Kirkpatrick et al., 1997) in patients with both rheumatoid arthritis (RA) and OA. 
Histological specimens obtained from patients with OA have shown positive staining for 
YKL-40 in chondrocytes mainly in the superficial and middle zones of the cartilage whereas 
it was low or undetectable in normal cartilage samples (Volek et al., 1999). Elevated levels 
of both serum and synovial fluid YKL-40 are seen in patients with active RA or severe knee 
OA in comparison to normal subjects (Johansen et al., 1993; Johansen et al., 1996; Johansen 
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et al., 2000). Johansen and colleagues (2001) demonstrated that YKL-40 was produced in 
response to removal of chondrocytes from their native extracellular matrix environment 
related to joint injury and disruption of the cartilage framework. YKL-40 production may be 
mediated by cytokines and growth factors that have a regulatory effect on chondrocyte 
function, especially in inflammatory con.ditions of the joints such as OA. 
Other approaches in investigating the changes associated with OA, are to look at the 
synovium and the bone matrix. The synovium serves as a direct reservoir for molecules that 
are exchanged in the joint and are involved with joint integrity as well as end products that 
are degraded in cartilage metabolism. The bone matrix can be assessed in conditions such as 
OA using bone scintigraphy (Thomas et al., 1975). Bone scintigraphy is the use of a 
radionuclide tracer agent such as technetcium labeled phosphate to obtain an image of the 
joint. This imaging technique may supplement the physical examination and a simple 
radiography of the joint in assessing the severity of OA (Arnold et al., 1980; Dye and Chew, 
1993). 
Regeneration of Articular Cartilage 
Process of Cartilage Repair 
Physicians and scientists have sought ways to repair and regenerate the articular 
surface of synovial joints after the loss or degeneration of articular cartilage for more than 
200 years (Buckwalter et al., 1990). Little progress has been made during this time, except 
for the last few decades in which scientific investigations have shown that implantation of 
artificial matrices, growth factors, and chondrocytes can stimulate the formation of 
cartilaginous tissue in osteochondral and chondral defects of the synovialjoints (Buckwalter, 
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1992; Buckwalter, 1996a). Mechanical loading of the joints also can influence the healing 
and repair process. 
Several surgi9al procedures to treat OA including osteotomy, penetration of 
subchondral bone, and joint distraction and motion have seem to stimulate formation of new 
cartilage surfaces (Mitchell and Shepard, 1976; Buckwalter and Mankin, 1997). However, 
inadequate approaches to assessing the results of these surgical procedures have made it 
difficult to evaluate their relative success in restoring the function of the joint (Hass, 1944; 
Buckwalter and Lomander, 1994). 
A better understanding of the degeneration of the articular cartilage and the 
recognition of the limitations of current treatments have also contributed to the recent 
interest in the repair and regeneration of cartilage (Buckwalter and Mankin, 1997). Advances 
in the imaging and arthroscopic techniques of synovial joints have led to an increased 
knowledge of frequency and types of defects and the possibility to diagnose and evaluate 
them with great accuracy (Buckwalter and Lomander, 1994; Buckwalter, 1996a). Ultimately, 
the regeneration of normal articular cartilage may not be necessary in order for a procedure 
to beneficial because stimulating the formation of cartilage repair tissue may decrease 
symptoms and improve joint function (Buckwalter, 1996b ). Clinical reports on procedures 
intended to restore a damaged or degenerated articular cartilage have shown improvements 
in more than 75% of the patients (Hass, 1944; Bert, 1993; Buckwalter et al., 1994; 
Buckwalter, 1996a). However, interpretation of these reports is complicated by variability, 
patient age, and the types of defects. 
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Current Treatments and Therapies for QA-Surgical 
Stimulating New Cartilage Growth 
Penetration of subchondral bone is a commonly used technique to stimulate the 
formation of new articular surface (Engkvist and Johansson, 1980; Homminga et al., 1990). 
It is a method to disrupt subchondral blood vessels and excise the damaged cartilage along 
with the underlying subchondral bone. Another surgical method is arthroscopic abrasion 
which can successfully decrease the symptoms of osteoarthritis of the knee joint by 
stimulating the formation of a fibrocartilaginous articular surface that varies in composition 
in relation to its collagen meshwork (Bert and Maschka, 1989; Bert, 1993). Radiographic 
evidence indicates an increase in joint space after the abrasion technique which presumably 
means the formation of new articular surface. However, arthroscopic abrasion did little to 
relieving the symptoms of OA (Bert, 1993). 
Osteotomy 
Osteotomy has been the method of choice for surgeons in treatment of hip and knee 
joints with localized loss or degeneration of the articular surface (Coventary, 1979; Noyes et 
al., 1993; Millis et al., 1995; Trousdale et al., 1995). In rare cases, it is combined with the 
penetration of the subchondral joint where it may involve another afflicted joint. Osteotomy 
is used to decrease the load on the most severely damaged regions of the joint surface and to 
bring regions of the joint surface that have the remaining articular cartilage into opposition 
with regions that lack the cartilage. Clinical experience with this procedure has been 
effective in decreasing the symptoms and stimulating the formation of new articular surface 
(Millis et al., 1995; Trousdale et al., 1995). However, the mechanisms for this improvement 
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remain poorly understood (Millis et al., 1995). Long-term follow-up of patients with 
osteotomy for osteoarthritic hip or knee joint have shown that the clinical results deteriorate 
over time (Trousdale et al., 1995; Iwase et al., 1996; Perlau et al., 1996). Variables that 
appear to affect the results of knee osteotomy adversely include older age, obesity, severe 
degeneration, limited motion of the knee, surgical overcorrection or undercorrection, and 
postoperative loss of correction (Hernigou et al., 1987; Finkelstein et al., 1996). Even 
patients who appear to be ideal osteotomy candidates and have an initial good outcome, tend 
to have recurrent pain and evidence of progressive osteoarthritis with time (Finkelstein et al., 
1996). 
Soft-Tissue Grafts 
Treatment of osteoarthritic joints with soft-tissue grafts includes benefits such as new 
cell populations along with an organic matrix. The success of soft-tissue arthroplasty 
depends not only on the severity of the abnormalities of the joint and on the type of graft but 
also on the postoperative motion to facilitate the generation of a new articular surface 
(O'Driscoll and Salter, 1986;0'Driscoll et al., 1988). Bothperichondral and periosteal grafts 
placed on articular cartilage defects have produced new cartilage in animal models as well as 
clinical studies (O'Driscoll and Salter, 1986; O'Driscoll et al., 1988). 
Age of the patient may also influence the effectiveness of grafts. Best results were 
produced in younger patients where the ability of undifferentiated cells or chondrocytes to 
form articular cartilage was greatest. The limited ability of host cells to restore articular 
surface has made it necessary to seek alternative methods to transplant cells that can form 
cartilage. Studies have shown that both chondrocytes and undifferentiated mesenchymal 
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cells placed in articular cartilage defects survive and produce new cartilage matrix (Itay et 
al., 1987; Wakitani et al., 1989). Other studies have also indicated that the transplantation of 
chondrocytes combined with the use of a tissue graft can promote the restoration of an 
articular surface in humans (Itay et al., 1988; Noguchi et al., 1994). Future research is needed 
to assess the function and durability of the newly formed cartilage tissue, to determine if it 
improves joint function and delays or prevents joint degeneration, and to be certain that these 
approaches are beneficial in treating osteoarthritic joints. 
Current Treatments and Therapies for QA-Lifestyle 
Unloading of the Joint 
The relationship between joint use and joint degeneration is a critical part in 
developing strategies to prevent and treat OA (Hochberg et al., 1995; Minor, 1999). Both 
animal and human joint studies have shown that moderate and even strenuous regular 
activity does not cause or accelerate the development of osteoarthritis in normal joints 
(Buckwalter, 1995; Buckwalter and Lane, 1996). Furthermore, cyclic loading of cartilage 
stimulates matrix synthesis whereas prolonged static loading or the absence of loading and 
motion causes degradation of the matrix as well as the joint (Fisher and Pendergast, 1994; 
Lane, 1995). 
Decreased contact pressures of the articular surfaces combined with movement of the 
joint may stimulate the restoration of an articular surface on osteoarthritic joints. Before the 
development of artificial joints, it was found that the resection of an osteoarthritic joint 
surface followed by decreased loading combined with motion of the joint resulted in the 
formation of fibrocartilaginous tissue over the osseous surfaces (Buckwalter and Lohmander, 
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1994). It has also been suggested that decreased loading of the joint by releasing the muscles 
that act across the degenerated hip joint can decrease symptoms and increase the 
radiographic cartilage space in some patients (Buckwalter and Mow, 2001). 
Current Treatments and Therapies for QA-Medications 
Classes of Non-Steroidal Anti-Inflammatory Agents 
The choice of effective treatments for individuals with OA is quite a challenge. The 
concensus recommendation for patients with OA has been to use acetaminophen (Bradley et 
al., 1991) Their studies were also able to compare the effects of various doses of 
acetaminophen alone and in comparison with doses of ibuprofen (Brandt, 1991; Bradley et 
al., 1992). The effectiveness of these two agents has been investigated in treating patients 
with OA of the hip and knee where the outcome measures included the patient's self-
assessment functional scores using the W estem Ontario and MacMaster Universities 
Osteoarthritis Index (WOMAC). These studies included the multi-dimensional Health 
Assessment Questionnaire which measures the quality of life of patients with arthritis 
(Bellamy et al., 1988; Pincus et al., 1999). Overall, acetaminophen has been shown to be 
more tolerable with less gastrointestinal distress in comparison to ibuprofen. Acetaminophen 
is an excellent analgesic but does not possess any anti-inflammatory activity (Towheed and 
Hochberg, 1997). Its mechanism of action is not clearly known however at high doses it has 
been shown to inhibit prostaglandin synthesis (Cryer and Feldman, 1998). The adverse 
effects with the use of acetaminophen have been due to acute overdose which is associated 
with liver damage. Furthermore, in a case-controlled study, chronic use can lead to kidney 
failure in some individuals (Hochberg et al., 1995). 
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Celecoxib and Rofecoxib 
The new class of non-steroidal anti-inflammatory drugs (NSAIDs) has shown vastly 
improved function in OA and rheumatoid arthritis patients with similar efficacy to their 
predecessors but with significantly decreased gastrointestinal and platelet effects (Simon et 
al., 1999; Laine et al., 1999). Americans use these agents on a daily basis and according to 
the projected statistics by the US Center for Disease Control and Prevention, it is likely that a 
significant increase in the prevalence of painful and degenerative. conditions will likely 
increase the use ofNSAIDs (Baum, 1985; Phillips and Simon, 1997). The newer class of 
NSAIDs selectively inhibit cycloxygenase-2 (COX-2) more so then COX-1. This makes 
them more potent anti-inflammatory agents for degenerative joint conditions such as OA 
without causing detrimental effects on the gastrointestinal tract. 
The most commonly used therapeutic compounds for OA in this class are called 
celecoxib and rofecoxib (Lipsky et al., 1998). Both of these compounds are selective COX-2 
inhibitors and have been shown to be effective in reducing or alleviating OA pain and 
inflammation associated with rheumatoid arthritis (Simon et al., 1998; Benson et al., 1999; 
Ehrich et al., 1999; Hawkey et al., 1999; Laine et al., 1999; Laine et al., 1999; Simon et al., 
1999). These studies also presented clear evidence of no endoscopic gastroduodenal damage 
and no adverse effect on platelet aggregation (Simon et al., 1998; Benson et al, 1999; Ehrich 
et al., 1999; Hawkey et al., 1999; Laine et al., 1999; Laine et al., 1999; Simon et al., 1999). 
However, many of these studies have left the renal effects of these potent COX-2 inhibitors 
unanswered. Several mechanisms being proposed for these anti-inflammatory compounds 
include their in vitro inhibition of inducible nitric oxide synthase which subsequently 
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decreases the production of nitrite (Amin et al., 1995; Pelletier, 1999). It has also been 
suggested that NSAIDs, by inhibiting prostaglandin production could also be responsible in 
reestablishing a more normal cell cycle response which is inhibited by prostaglandins 
(Patrignani et al., 1994; Dubois et al., 1998; Crofford et al., 2000). Longer-term effects of 
these agents are not yet fully understood in context of their toxic load on the liver as well as 
their adverse effects on other tissues and organ systems. 
Current Treatments and Therapies for OA-Nutraceuticals 
Biological compounds represent newer potential therapies for OA and these include 
chondroitin sulfate, glucosamine sulfate, and glucosamine hydrochloride (Lozada and 
Altman, 1997). These nutritional supplements are being widely used for the treatment of 
painful OA of the knee, hip and hand but their effectiveness is uncertain (Hauselmann et al., 
2001 ). In earlier studies, the potential effects of these agents were mostly from small and not 
well designed studies of short duration and mostly conducted overseas in Europe and Asia. 
Recent studies with better designs and more patients for longer duration have found that 
glucosamine sulfate and chondrotin sulfate have modest to excellent effects on controlling 
pain and improving function in comparison to placebo and are comparable to NSAIDs. 
These studies have also demonstrated fewer adverse side effects related to the 
gastrointestinal system (McAlindon et al., 2000). 
Glucosamine Sulfate 
Basic scientific research on the effects of glucosamine sulfate has been supported by 
recent in vitro studies of cultured human and animal chondrocytes showing that it stimulates 
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glycosaminoglycan synthesis (Bassleer et al., 1998; Gouze et al., 2001) and reduces 
catabolism (Jimenez, 1996; Sandy et al., 1998). Its proposed mechanism is a dose-dependent 
inhibition of pro-inflammatory cytokines such as IL-fl. fu the clinical setting, the data to 
support the benefits of glucosamine have been limited by sample size, effect size, and 
outcome measures. There are three double-blinded and placebo controlled human studies 
which have assessed the short-term effects of glucosamine sulfate as determined by 
improvements in pain, joint tenderness, and swelling (Drovanti et al., 1980; Pujalte et al., 
1980; Noack et al., 1994). Additionally, the study by Drovanti and colleagues has 
investigated the cellular morphology of the cartilage tissue using scanning electron 
microscopy in subjects on both placebo as well as glucosamine. Their findings have shown a 
healthier cartilage structure and chondrocyte morphology in those individuals treated with 
glucosamine (Drovanti et al., 1980). 
Several studies have also compared the effects of glucosamine sulfate with ibuprofen. 
fu one particular study where patients received glucosamine (500 mg three times per day) or 
ibuprofen (1,200 mg per day) for a period of 8 weeks, it was shown that the rate of 
improvement as defined by reduction in pain became progressively pronounced in the 
glucosamine group than in the ibuprofen group (Vaz, 1982). fu a shorter duration study ( 4 
weeks), it was found that the reduction in pain occurred earlier in the study with the 
ibuprofen group then the glucosamine group, but there were no differences in effect between 
the two treatment groups from the second week onward (Qui et al., 1998). Both glucosamine 
and ibuprofen reduced symptoms of OA with a trend showing glucosamine to be more 
effective. More importantly, the beneficial effects were greater after the treatments were 
discontinued indicating a greater residual effect of glucosamine (Qui et al., 1998). Other 
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short-term studies have also confirmed the beneficial residual effect of glucosamine and 
suggest a favorable influence on the disease process (Rovati et al., 1994). More recent 
studies with glucosamine have utilized the Western Ontario-McMaster University 
(WOMAC) pain subscale scores as the primary endpoint to assess the degree of change 
(Houpt et al., 1999). Changes in the WOMAC pain scores favor glucosamine over placebo, 
but these differences were not significant. Positive trends were noted for glucosamine for 
majority of the questions in this pain assessment questionnaire. The only long-term study of 
glucosamine, as a potential disease-modifying agent, has shown positive results with respect 
to cartilage preservation (Reginster et al., 2001). However, this claim cannot be established 
due to a lack of proper and standardized radiographic techniques in measuring the knee joint 
and assessing the positive changes in cartilage tissue associated with glucosamine. 
Chondroitin Sulfate 
Chondroitin sulfate is part of the proteoglycan macromolecule which is responsible for 
giving cartilage its resiliency (Hauselmann et al., 2001 ). In vitro using human chondrocytes 
and in vivo animal studies have shown that chondroitin inhibits cartilage loss by causing a 
dose-dependent decrease in collagenase activity (Bassleer et al., 1998; Uebelhart et al., 
1998). Short term studies of oral chondroitin sulfate have shown that individuals with knee 
OA receiving chondroitin used fewer NSAIDs then those individuals on placebo over the 
treatment phase as well as during the two-month follow-up (Mazieres et al., 2001). fu 
another 3-month study, patients in the chondroitin group experienced a more prolonged 
improvement in categorical measurement of pain and a reduction in the use of pain 
medication (Morreale et al., 1996). 
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In a one-year study, Uebelhart and colleagues (1998) studied the potential disease 
modification role of chondrotin sulfate in 42 patients with knee OA. Outcomes measures 
included measurement of joint space width which the authors reported to be stabilized in a 
number of patients who received chondroitin sulfate (Uebelhart et al., 1998). Most studies 
have focused on the effects of chondroitin sulfate or glucosamine sulfate alone, but not on 
their combination. However, one, 16-week study was conducted to evaluate the combination 
effect of glucosamine and chondroitin sulfate in men with pain and radiographic evidence of 
knee OA (Leffler et al., 1999).These patients reported an overall improvement in the visual 
analog scale of pain, physical functioning of the afflicted knee, and ease in performing 
activities of daily living. It is necessary that both glucosamine and chondroitin sulfate should 
be further evaluated in longer duration studies with longer follow-up periods to substantiate 
their claim that they are disease and structural modifying agents. 
44 
CHAPTERIII 
EVIDENCE FOR THE PRESENCE OF ESTROGEN RECEPTORS IN HUMAN 
ARTICULAR CARTILAGE 
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Summary 
Objective: The present study explores the possible connection between synovial fluid 
concentrations of 17P-estradiol (E2), the presence of estrogen receptors in articular 
cartilage, and knee osteoarthritis (OA). 
Methods: Knee cartilage and synovial fluid specimens were obtained from a total of 
thirty-four individuals (21 females and 13 males) with and without OA. Total RNA was 
isolated from cartilage specimens to determine the presence ofERq ERP and aromatase 
using reverse-transcriptase polymerase chain reaction (RT-PCR). Immunocytochemical 
analysis was conducted to confirm the presence and location of the estrogen receptors in 
cartilage tissue. Additionally, western blot analysis was used to examine the relative 
abundance of ERa and ERP protein in cartilage tissue. Synovial fluid specimens were 
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analyzed to determine Ez concentrations . 
. Results: The presence of mRNA for both estrogen receptors a and J3 was detected in 
human articular cartilage. In women afflicted with OA, ERJ3 expression was significantly 
higher (P < 0.0001) than non-osteoarthritic women. There were no differences observed 
in ERa expression in women with or without OA. No differences were observed in 
ERa and ERJ3 expressions in men with and without OA. hnmunocytochemical staining 
techniques confirmed the presence of these receptors as well as its localization within the 
cartilage cells. Western blot analysis confirmed the presence of proteins for these 
receptors. Synovial fluid concentrations ofE2 were significantly (P < 0.03) elevated in 
women with knee OA compared to their normal counterparts when normalized to total 
protein. However, E2 levels of synovial fluid ·were not affected by OA in men. 
Additionally, women with OA expressed higher levels of mRNA for aromatase compared 
to those without OA. Expression of mRNA for aromatase in men with or without OA 
were not different. 
Conclusion: This study provides initial evidence for the higher ERJ3 expression, but not 
ERa in women with OA compared to without OA, No such differences in ERs were 
observed in men. In women, the elevated levels of E2 in synovial fluid may, in part, be 
explained by higher aromatase activity as evident by elevated mRNA expressions. The 
presence ofERs along with increased E2 concentrations may contribute to the 
pathophysiology of OA in women. The functional role of the ERs and their subtypes in 
cartilage metabolism in conditions such as osteoarthritis needs to be further clarified. 
Key words: aromatase, cartilage, estrogen receptors, osteoarthritis, synovial fluid 
46 
Osteoarthritis (OA) is the most common joint disorder of both men and women and 
its etiology is relatively unknown (1 ). The prevalence and severity of OA increases with 
age with the knee joint being one of the most commonly afflicted joints. OA of the knee 
involves a narrowing of the joint space that is usually evident by x-ray radiography (2). 
Epidemiological surveys have suggested sex-associated differences related to age and 
disease severity (3). The prevalence of OA is higher in men than in women up to 
approximately age 45, however, after age 45 the reverse is true. The predominance of 
generalized OA in women suggests that changes in production and nature of estrogens 
may be risk factors in the development of OA. 
Although the incidence of knee OA is greatest in postmenopausal women, its link to 
sex hormones is undetermined and seems conflicting. For instance, epidemiological 
studies point to a lower incidence of OA and more knee cartilage in women who are 
long-term users of estrogen replacement therapy ( 4, 5). Yet, experimental studies imply a 
detrimental role of estrogen on cartilage metabolism. For instance, some animal studies 
have demonstrated that when estrogen is administered directly to the knee joint, it results 
in an increased frequency and severity of OA (6,7). Estrogen has also been shown to 
modulate cartilage metabolism, as evident by its suppression of proteoglycan synthesis 
(8). Additionally, intraarticular injection of 17~-estradiol to the knee joint impairs lactate 
dehydrogenase in chondrocytes, an event preceding the disruption of matrix collagen (9). 
These observations imply that estrogen is involved in the etiology of OA and that it could 
affect chondrocyte metabolism and proliferation, possibly through a receptor-mediated 
mechanism. 
Of significance is that the incidence of OA does not seem to be related to circulating 
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levels of estrogen (2). Rather, excessive levels of synovial fluid estrogen, without 
noticeable differences in circulating estradiol levels, may contribute to the development 
of OA in humans (10). Furthermore, the effects of estrogen on cartilage may not be 
confined to females but may also apply to males. Higher synovial estradiol and higher 
estrogen receptor levels in cartilage have been suggested by Rosner et al. (11) two 
decades ago as possible primary reasons for the incidence of OA in males as well. 
If cartilage is to be considered a direct target tissue for estrogens, then estrogen 
receptors (ERs) are expected to be present in human cartilage. Hence, the current study 
was conducted to evaluate: 1) whether there are differences in synovial estradiol levels 
between osteoarthritic and nonosteoarthritic joints in males and females and 2) whether 
there is a relationship between the presence ofERs and knee OA. 
MATERIALS AND METHODS 
Subjects and tissue collection. The purpose of this study was to elucidate the presence 
of ERs in human cartilage and whether there is a relationship between the expression of 
ERs and E2 concentrations in synovial fluid of men and women with OA in comparison 
to individuals without OA. The study protocol and consent form were approved by the 
Oklahoma State University Institutional Review Board. Knee cartilage and synovial fluid 
specimens were obtained from a total of thirty-four individuals (Table 1) with and 
without OA. Based on patient history, the incidence of knee OA in these individuals was 
unrelated to traumatic injury to the joints. Of these, 4 males and 14 females were afflicted 
with knee OA and the remaining 9 males and 7 females were controls who either had 
48 
recent knee injury or repeated knee injuries but had no evidence of OA as diagnosed by 
their orthopedic surgeon (Table 1). These subjects were referred to the surgeon for the 
repair of their knees, and were otherwise considered healthy. On the day of surgery, 
synovial fluid was collected, aliquoted, and stored in -80°C for analyses. Articular 
cartilage specimens removed during routine surgical repair were immediately collected 
and stored in ice, separated, processed for isolation of total RNA and 
immunocytochemistry and stored at -80°C for receptor analyses. Additionally, uterine 
and ovarian tissue specimens were obtained from volunteers undergoing hysterectomy 
and served as positive controls for receptor and reverse-transcriptase polymerase chain 
reaction (RT-PCR) analyses. 
The joints of patients with insignificant levels of synovial fluid were irrigated with 
1 to 2 ml of normal saline and subsequent analyses were normalized to the synovial total 
protein concentration. Total protein concentrations in the synovial fluid were determined 
using reagents from Roche Diagnostics (Montclair, NJ) and analyzed by the Cobas-Fara 
II Clinical Analyzer. Briefly, 10 µL of synovial fluid was incubated with the dye reagent 
concentrate resulting in a color change in response to various concentrations of protein. A 
standard curve for this assay was ·simultaneously determined using lyophilized 
preparations of bovine plasma albumin which was reconstituted with deionized water. 
The absorbance of this colormetric reaction was measured at 570 nm and the synovial 
fluid total protein concentrations were calculated using the standard curve. Subsequently 
the synovial fluid E2 values were corrected based on total protein levels and reported as 
pg E2/mg protein. 
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RNA isolation and reverse-transcriptase polymerase-chain reaction.. Total cellular 
RNA was extracted from articular cartilage and uterine tissues using the acid-phenol 
extraction method ofChomczynski and Sacchi (12) and reverse transcriptase-polymerase 
chain reaction (RT-PCR) was performed as described by Malayer and Woods (13). 
Briefly, for each tissue, two micrograms of total RNA was denatured by heating at 95°C 
and reverse transcribed in the presence of random hexamers (pdN6; 100 pmol; Pharmacia, 
Piscataway, NJ), dATP, dTTP, dCTP, and dGTP (dNTPs; 250µmol; Pharmacia), MgCh 
RNase inhibitor (20 U per reaction; Promega, Madison, WI), and reverse transcriptase 
(Superscript™ 200 U per reaction; Gibco BRL) at 37°C for 75 min. The reaction was 
stopped by heating at 95°C. Aliquots of reverse-transcribed cDNA (2µ1) are denatured by 
heating at 95°C and subjected to polymerase chain-reaction in the presence of75 pmole 
specific primers, MgCh, dNTPs (25µmole), and Amplitaq™ DNA polymerase (0.5 U 
per reaction; Perkin-Elmer, Foster City, CA) in 20 µ1 reaction. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene was amplified separately to confirm the 
integrity of the isolated RNA and as an internal standard. The primers were prepared 
according to the published sequence of the human gene for ER~ (14), ER~ (15), 
aromatase (16), and GAPDH(17) and are shown in Table 1. Products of the RT-PCR 
were resolved on 1.2% agarose-TAE gels [Tris-acetate (40 mmole), EDTA (1 mmole)]. 
Gels were briefly stained with etidium bromide dye solution for visualization using a UV 
box. Gene products were quantified using a BIORAD densitometer and Gel 
Documentation Software (Hercules, CA) 
Western blot analysis. The protein levels ofERa and ERP were detected by the method 
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ofTowbin et al. (18) with some modification. A 25 µg cytosolic fraction of each cartilage 
sample was mixed with the gel loading buffer, pH 6.8, (0.125 M 
Tris[hydroxymethyl]aminomethane, 4% sodium dodecyl sulfate (SDS), 20% glycerol, 
10% 2-mercaptoethanol, and 0.2% bromophenol blue) in ratio of 1: 1 and boiled for 5 
minutes. This was then separated on a 8% SDS-polyacrylamide mini-gel at 100 V, and 
transferred to polyvinylidene fluoride membrane at 15 V for 1 hour using a semi-dry 
transfer system (BIO-RAD, Hercules, CA). The membrane was immediately placed in a 
blocking solution (5% non-fat dry milk in TBS-T buffer containing 50 mM Tris, 150 mM 
NaCl, and 0.1 % Tween 20, pH 7 .5) at 4 °C for overnight incubation. The membrane was 
then incubated with a mouse monoclonal ERa ( diluted 1 :200 in TBS-T buffer) and a 
rabbit polyclonal ERP ( diluted 1 :200 in TBS-T buffer) at room temperature for 1 hr. 
After three consecutive rinses in washing buffer containing 50 mM Tris, 150 mM NaCl, 
0.1 % SDS, 0.1 % NP-40, 0.5% deoxycholic acid, pH 7.5 for 10 minutes per wash, the 
membrane was incubated with a horseradish peroxidase-conjugated goat anti-mouse 
antibody (5% non-fat milk, diluted 1:1000 in TBS-T buffer) and goat anti-rabbit 
secondary antibody (5% non-fat milk, diluted 1 :2000 in TBS-T buffer) at room 
temperature for 45 minutes. Following four rinses with washing buffer, a secondary 
antibody labeling system was used to detect the enhanced chemiluminescence. The 
membrane was then exposed to Hyperfilm. Pre-stained blue protein markers was used for 
the accuracy of molecular weight determination of the protein of interest. Protein levels 
of ERa and ERP were quantified using BIO RAD densitometer and Gel Documentation 
Software (Hercules, CA) 
Immunocytochemistry analyses. Immunocytochemistry was carried out to determine 
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whether human cartilage contains immunoreactive estrogen receptor alpha and beta 
proteins, and if present to examine the abundance of the immunoreactive cells. Since 
uterine tissue is known to be rich in ERs, it was used as positive control tissue (19). The 
tissues were cut into small pieces, mounted on tissue molds, frozen with liquid 2-methyl 
butane and stored at -80°C. Frozen sections, 6 µm thick, were prepared using a cryostat 
(Bright Clinicut, Huntington, England) and thaw-mounted onto glass slides coated with 
poly-L-lysine. The sections were fixed for 10 min in 3.7% paraformaldehyde in 0.4 
mole/L phosphate buffered-saline (PBS) at a pH of 7 .3, and subsequently rinsed for 5 min 
in PBS. The slides were immersed in cold methanol and acetone and then washed with 
PBS buffer. The slides were then transferred to fresh stock of PBS buffer and held for no 
more than an hour until the primary antibody dilutions with and without blocking 
peptides were prepared. The slides were then incubated overnight in a humidified 
chamber at 4°C with antibodies against human estrogen receptors alpha or beta. The 
following day the sections were processed by the avidin-biotin peroxidase complex 
(ABC; Vector Laboratories, Inc. Burlingame, CA) procedure of Hsu, et al (20) at room 
temperature using the reagents and protocol supplied in the ABC kit from the 
manufacturer. The reaction products were immersed in subsequent washes of PBS buffer 
and visualized with a chromogen, diaminobenzidine (DAB) stain. Specificity of the ER 
antiserum was determined from control studies. In control studies, the ER antiserum was 
replaced with either normal serum or antibodies against ERa. and ERl3 which were 
pre-incubated with excess of the peptides used to raise these antibodies (21,22). 
Synovial fluid estradiol. 1713-Estradiol concentrations were measured using 
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radioimmunoassay (RIA; Diagnostic Products Corp, CA) techniques. Briefly, aliquoted 
samples were thawed and centrifuged at 2400 x g for 2 min (23). A 10 µL aliquot of 
synovial fluid were incubated in antibody-coated tubes in the presence of 100 µL of 
[125I]-labeled E2 at room temperature following the manufacturer's protocol. The tubes 
were decanted and counted in gamma counter. The standards and controls provided in the 
RIA kit were used simultaneously according to the manufacturer's protocol in 
determining a log-logit curve (see Appendix A). The estrogen concentrations in the 
synovial fluid specimens were determined using this log-logit curve. Synovial fluid 
estradiol values were then corrected based on total protein levels and reported as pg/mg 
protein. 
Statistical analysis. Data analysis involved estimation of means, standard error of mean 
(SE), and analysis of variance using InStat Software (Version 3.0; San Diego, CA). 
When the analysis of variance indicated significant difference, the differences among 
means were investigated using the Tukey's multiple comparison procedure. P<0.05 was 
considered statistically significant. 
RESULTS 
In the present study, it should be noted that the volume of synovial fluid was 
limited which restricted our ability to perform the validation test for the concentrations of 
E2• Another limitation is that certain joints had to be lavaged by using 1 to 2 mL of saline, 
therefore we could no longer assess the estradiol levels per mL synovial fluid. That is the 
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reason for reporting synovial fluid Ez values per mg protein. This type of normalization 
has not been reported in the literature and the reproducibility of our data needs to be 
confirmed. Another point that should be mentioned is that there are currently no RIA kits 
specifically designed to assess the concentrations ofE2 in the synovial fluid and hence 
the reliability, specificity, and validity of this RIA kit for use in synovial fluid need to be 
addressed. 
Amplification of cDNA from articular cartilage tissues using RT-PCR showed the 
presence ofmRNA for ERP (Figures la and lb, females and males, respectively) and 
ERa (Figures 2a and 2b, females and males respectively). Integrity of the isolated RNA 
and equal loading of specimen for PCR amplification was confirmed using GAPDH 
(Figures 1 a , 1 b, 2a, and 2b ). When PCR products for ERa (Figure 3) and ERP (Figure 4) 
were standardized to GAPDH, only ERP was greater in articular cartilage specimens 
obtained from women with osteoarthritic joints compared to specimens that were 
obtained from nonosteoarthritic women. Western blot analyses confirmed the increase in 
protein levels of ERP, but not ERa in women with OA in comparison to individuals 
without OA (Figure 5a and 5b ). 
Positive nuclei immunostaining confirmed the presence of both ERa (Figure 6a and 
6b) and ERP (Figure 7 a and 7b) in the cartilage specimens obtained from patients with 
OA. hnmunostaining technique for these receptors was verified by their presence in 
positive control tissues (Figure 8a and 8b ). Similar tissues when incubated with an excess 
of peptide used to produce the antibody did not show specific stainings ( data not shown). 
The mRNA levels of aromatase standardized to GADPH were higher in women 
with OA than those without OA (Figure 9). No differences between aromatase mRNA 
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levels were observed among men (Figure 10). 
Synovial fluid specimens from female patients with OA had significantly higher 
concentrations ofE2 in comparison with those of non-osteoarthritic females or males with 
or without OA (Figure 11). However, there were no statistically significant differences in 
E2 levels of synovial fluid between men with or without OA. 
DISCUSSION 
The findings of this study suggest the presence of both ERa and ERf3 in articular 
cartilage with greater abundance of ERf3 compared to ERa, indicating that there may be a 
functional role for the ERf3-subtype specific to the tissue. ERf3 subtype was cloned by 
Kupier et al. (24) and appears to be distinctively different from the classical ERa in its 
role in gene regulation. Findings from this study using RT-PCR and 
immunocytochemical techniques indicated the presence of both ERa and ERf3 in articular 
cartilage specimens obtained from both men and women with OA. According to our RT-
PCR and western blot analyses, we have observed that both the mRNA and protein levels 
of ERf3 are greater in women afflicted with OA. This suggests that there may be a cause 
and effect relationship that exists between the incidence of OA and the presence of ERf3 
in this tissue. It is possible that this is analogous to the presence ofERa in mammary 
tissues and its connection with breast cancer (25,26). However, further investigation is 
needed to confirm whether such a relationship exists. 
Our findings of estrogen receptors in cartilage are in agreement with two previously 
published reports (27,28). Initially, Nilsson and colleagues (27) reported the presence of 
55 
ERP in human growth plate cartilage but were unable to detect the presence of ERa 
protein using Western blot analysis. A more recent study by Ushiyama et al. (28) 
indicated the presence of both ERa and ERP in human articular cartilage obtained from 
men and women with and without OA using RT-PCR techniques. In this present study, 
we utilized both techniques used by these investigators and were able to confirm the 
presence of both ER subtypes. 
Our results indicated that the synovial fluid concentrations of E2 were significantly 
greater in women with OA as compared to those without OA or men with or without OA. 
Hence, higher levels of estrogen in synovial fluid may play a role in the etiology of OA in 
women but not in men. Whether a synonymous relationship exists in men with respect to 
androgen concentrations has to be investigated. The higher Ez concentrations in synovial 
fluid of women with OA leads us to speculate that localized E2 in the synovial cavity may 
be involved in the degenerative process of cartilage. The accumulation of estrogen in the 
synovial fluid of women with OA, in part, may be explained by increased aromatase 
activity as evidenced by higher mRNA expression for aromatase. 
It is important to pointout that our findings are based on a very limited number of 
subjects and specimens. Therefore, these findings cannot be extrapolated to populations 
with OA and the data are at best preliminary in nature. Hence, it would be necessary to 
validate these findings in future studies with larger sample size from both men and 
women with and without OA. 
If elevations in E2 are implicated in cartilage degeneration leading to OA, then 
agents such as selective estrogen receptor modulators (SERMs) may be able to compete 
with estrogens in occupying ERP present in the knee cartilage and perhaps negate its 
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deleterious effects. Selective estrogen receptor modulators are defined as a group of 
compounds behaving as estrogen agonists in certain tissues while acting as antagonists in 
some other tissues (29). To this date, ERP has been found in certain tissues including 
brain, bone, bladder, and vascular epithelial which are responsive to estrogen as well as 
SERMs (30). Recent investigations on the effects of synthetic and naturally occurring 
SERMs on various tissues suggest that these diverse molecules may influence target 
tissues by exerting their effects mainly through ERP (31 ). The tissue distribution of these 
two ERs differs (30) which may explain the agonistic or antagonistic properties of 
SERMs in various tissues. Therefore, cells that preferentially express ERP, including 
cartilage cells, are more likely to respond to SERMs. However, this concept is 
speculative and requires further investigation. The impact of SERMs such as genistein, 
ipri:flavone, raloxifene on improvement of OA conditions remains to be shown. 
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Table I 
Description of study participants 
Gender Status of Knee Joint N= MeanAge±SE 
N-OA 7 39.7 ± 2.9 
Female 
OA 14 57.8 ± 5.5 
N-OA 9 42.7 ± 3.9 
Male 
OA 4 59.8 ± 10.5 
Non-Osteoarthritis (N-OA); Osteoarthritis (OA) 
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Table II 
Primer sequences of gene products for RT-PCR 
Gene Sequence Size 
(bp) 
Aromatase Sense 5'-TACTACAACCGGGTATATGG-3' 503 
Anti-sense 5'-TGTTAGAGGTGTCCAGCATG-3' 
ERa Sense 5' -GACCGAAGAGGAGGGAGAA-3 460 
Anti-sense 5' -CCAAGAGCAAGTTAGGAGCAA-3' 
ER~ Sense 5' -TAGTGGTCCATCGCCAGTTAT-3' 323 
Anti-sense 5' -GGGAGCCACACTTCACCAT-3' 
Sense (nested) 5' -CGGAACCTCAAAAGAGTCCCTGG-3' 285 
Anti-sense (nested) 5 '-CCGAAGTCGGCAGGCCTGGCAGC-3' 
GAPDH Sense 5' -GAGTCAACGGATTTGGTCGT-3' 156 
Anti-sense 5 '-GGTGCCATGGAATTTGCCAT-3' 
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Figure lA 
285bp + 
123 4 5 6 7 8 91011 
Representative RT-PCR analysis for detection of estrogen receptor (13) in female cartilage 
specimens.Lane 1 represents the 100 bp ladder. Lane 2 represents negative control 
(water). Lanes 3-6 are amplification of cDNA from female cartilage without OA. Lanes 
7-10 are from female cartilage with OA. Lane 11 is amplification of cDNA from female 
uterine tissue (positive control). Products are expected size of 285bp length resolved on a 
Tris-actetate-EDTA agarose gel. 
123 45 67 8 9 
Integrity of the isolated RNA and equal loading of specimen for RT-PCR amplification 
was assured by assessing glyceraldehyde-3-phosphate dehyrdogenase (GAPDH) gene 
expression. Lanes 1-4 are amplification of cDNA from female cartilage without OA. 
Lanes 5-8 are from female cartilage with OA. Lane 9 is amplification of cDNA from 
female uterus (positive control) . Products are expected size of 156bp length resolved on a 
Tris-acetate-EDT A agarose gel. 
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Figure lB 
285bp ... 
1 2 3 4 5 6 7 8 91011 
Representative RT-PCR analysis for detection of estrogen receptor(~) in male cartilage 
specimensLane 1 represents the 100 bp ladder. Lane 2 represents negative control 
(water). Lanes 3-6 are amplification of cDNA from male cartilage without OA. Lanes 7-
10 are from male cartilage with OA. Lane 11 is amplification of cDNA from female 
uterus (positive control). Products are expected size of 285bp length resolved on a Tris-
actetate-EDTA agarose gel. 
12 3 4 5 67 8 9 
Integrity of the isolated RNA and equal loading of specimen for RT-PCR amplification 
was assured by assessing by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene 
expression. Lanes 1-4 are amplification of cDNA from male cartilage without OA. Lanes 
5-8 are from male cartilage with OA. Lane 9 is amplification of cDNA from female 
uterus (positive control). Products are expected size of l 56bp length resolved on a Tris-
acetate-EDT A agarose gel. 
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Figure 2A 
460bp 
123 4 5 6 7 8 91011 
Representative RT-PCR analysis for detection of estrogen receptor (a) in female cartilage 
specimens. Lane 1 represents the 100 bp ladder. Lane 2 represents negative control 
(water). Lanes 3-6 are amplification of cDNA from female cartilage without OA. Lanes 
7-10 are from female cartilage with OA. Lane 11 is amplification of cDNA from female 
ovary (positive control). Products are expected size of 460 bp length resolved on a Tris-
acetate-EDTA agarose gel. 
123 45 67 8 9 
Integrity of the isolated RNA and equal loading of specimen for RT-PCR amplification 
was assured by assessing glyceraldehyde-3-phosphate dehyrdogenase (GAPDH) gene 
expression. Lanes 1-4 are amplification of cDNA from female cartilage without OA. 
Lanes 5-8 are from female cartilage with OA. Lane 9 is amplification of cDNA from 
female uterus (positive control). Products are expected size of 156bp length resolved on a 
Tris-acetate-EDTA agarose gel. 
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Figure 2B 
460bp 
1234 5 6 7 8 91011 
Representative RT-PCR analysis for detection of estrogen receptor (a) in male cartilage 
specimens. Lane 1 represents the 100 bp ladder. Lane 2 is represent negative control 
(water). Lanes 3-6 are amplification of cDNA from male cartilage without OA. Lanes 7-
10 are from male cartilage with OA. Lane 11 is amplification of cDNA from female 
ovary (positive control). Products are expected size of 460bp length resolved on a Tris-
acetate-EDTA agarose gel. 
123 4 5 6 7 8 9 
Integrity of the isolated RNA and equal loading of specimen for RT-PCR amplification 
was assured by assessing GAPDH gene expression Lanes 1-4 are amplification of 
cDNA from male cartilage without OA. Lanes 5-8 are from male cartilage with OA. 
Lane 9 is amplification of cDNA from female uterus (positive control). Products are 
expected size of l 56bp length resolved on a Tris-acetate-EDT A agarose gel. 
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Figure 3 
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Gene expression for ERa in cartilage specimens standardized by glyceraldehyde-3-
phosphatase dehydrogenase (GAPDH) expression from male and female with and 
without osteoarthritis. Bars represent mean ± SE; n = 3-4. NOA, individuals without 
osteoarthritis; OA, individuals with osteoarthritis 
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4 
-E 
E 
E 
E 3 ci 
* 0 
-C'G 
-
Cl) 
.c 
I 
a:: 2 
w 
"C 
Cl) 
-ti) ::::, 
·-"C 1 C'G 
I 
J: 
C 
D.. 
ct 
C) 
0 
F-NOA F-OA M-NOA M-OA 
Gene expression for ER~ in cartilage specimens standardized by glyceraldehyde-3-
phosphatase dehydrogenase (GAPDH) expression from male and female with and 
without osteoarthritis. Bars represent mean ± SE; n = 3-4. * Asterisk denotes significantly 
(P < 0.0001) different then others. NOA, individuals without osteoarthritis; OA, 
individuals with osteoarthritis. 
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Figure SA 
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Representative Western blot analysis ofERa in cartilage specimens from male and 
female with and without osteoarthritis Bars represent mean± SE; n = 3-8; NOA (Non-
Osteoarthritis); OA (Osteoarthritis) 
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Representative Western blot analysis ofERf3 in cartilage specimens from male and 
female with and without osteoarthritis. Bars represent mean± SE; n = 3-8. * Asterisk 
denotes significantly (P < 0.05) different then others. NOA (Non-Osteoarthritis); OA 
(Osteoarthritis) 
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Figure 6a and 6b 
Immunocytochemical localization ofERa in human articular cartilage 
A 
B 
Figure A. An articular cartilage section incubated with polyclonal rabbit ERa antibody 
against human ERa. Figure B. A section of articular cartilage specimen incubated with 
normal rabbit serum (Magnification X 40). 
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Figure 7 a and b 
Immunocytochemical localization of ER~ in human articular cartilage 
A 
B 
Figure A. An articular cartilage section incubated with polyclonal rabbit ER~ antibody 
against human ER~. Figure B. A section of articular cartilage specimen incubated with 
normal rabbit serum (Magnification X 40). 
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A 
B 
Figure Sa and b 
Immunocytochemical localization ofERa and ERl3 in human ovary and uterine tissue 
used as positive control. 
Figure A. A section of ovarian tissue incubated with polyclonal rabbit ERa antibody 
against ERa. Figure B. A section from uterine tissue specimen incubated with polyclonal 
rabbit ERl3 antibody against human ERl3 (Magnification X 40) 
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Figure 9 
503bp .. 
-- . 
123 4 5 6 7 8 91011 
Representative RT-PCR analysis for detection of aromatase in female cartilage specimens 
Lane 1 represents the 100 bp ladder. Lanes 2-5 are amplification of cDNA from female 
cartilage without OA. Lanes 6-9 are cartilage specimen from female with OA. Lane 10 
represents negative control (water). Lane 11 is amplification of cDNA from female 
uterus (positive control). Products are expected size of 503bp length resolved on a Tris-
acetate-EDTA agarose gel. 
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Gene expression for aromatase standardized by glyceraldehyde-3 phosphate 
dehydrogenase (GAPDH) expression in cartilage from female with (F-OA) and without 
osteoarthritis (F-NOA). Bars represent mean+SE; n = 4 samples per group. * Asterisk 
denotes significantly (P < 0.05) different then others. 
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Figure 10 
503bp .. 
1 2 3 4 5 6 7 8 9 10 11 12 
RT-PCR analysis for detection of aromatase in male cartilage specimens 
Lane 1 represents the 100 bp ladder. Lanes 2-6 are amplification of cDNA from male 
cartilage without OA. Lanes 7-10 are from male cartilage with OA. Lane 11 represents 
negative control (water). Lane 12 is amplification of cDNA from female uterus (positive 
control). Products are expected size of 503bp length resolved on a Tris-acetate-EDT A 
agarose gel. 
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Gene expression for aromatase standardized by glyceraldehyde-3 phosphate 
dehydrogenase (GAPDH) expression in cartilage from male with (M-OA) and without 
osteoarthritis (M-NOA). Bars represent mean+SE; n = 4 samples per group. 
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Figure 11 
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Protein-normalized 17j3-estradiol concentrations in synovial fluid of men and women 
with and without osteoarthritis. Bars represent mean+SE; n = 5-9 samples per group. 
* Asterisk denotes significantly (P < 0.03) different then others. M, male; F, female; 
NOA, individuals without osteoarthritis; OA, individuals with osteoarthritis 
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CHAPTERIV 
WOMEN WITH OSTEOARTHRITIS HAVE ELEVATED SYNOVIAL FLUID 
LEVELS OF INSULIN-LIKE GROWTH FACTOR (IGF)-I AND 
IGF-BINDING PROTEIN-3 
Shanil Jum.a1, Dania A. Khalil\ Lisa Hammond\ Mark E. Munson\ Jerry Malayer2, 
Alvar Svanborg3, and Bahram H. Arjmandi1* 
1Department of Nutritional Sciences and 2Department of Physiological Sciences, School 
of Veterinary Medicine, Oklahoma State University; Stillw~ter, OK 7 4078 
3Department of Geriatric Medicine, Goteborg University, Gothenburg, Sweden 
Summary 
Objective: The present study explores the possible connection between synovial fluid 
concentrations of insulin like growth factor (IGF)-I, IGF-binding protein (IGFBP)-3 and 
leptin in osteoarthritis (OA). · 
Methods: Synovial fluid specimens were obtained from a total of thirty-four individuals 
(21 females and 13 males) with and without OA. Synovial fluid specimens were analyzed 
to determine IGF-I, IGFBP-3, leptin, and C-reactive protein (CRP) 
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concentrations. 
Results: The presence ofIGFBP-3 was detected in synovial fluid of both men and women 
with and without OA. Protein-normalized measurements ofIGF-1, IGFBP-3, and leptin 
concentrations in synovial fluid showed significantly (P < 0.05) elevated levels in women 
with knee QA but not in men. There were no significant differences in synovial fluid 
CRP concentrations in either gender with OA. 
Conclusion: This study provides initial evidence that protein normalized IGF-1 and 
IGFBP-3 and leptin levels increase in synovial fluid of women but not in men with OA 
versus those without QA. These findings, if confirmed imply that the etiology of OA 
differ in men versus women. These molecules though anabolic by nature are perhaps 
accumulated in the synovial fluid due the loss of their uptake by cartilage tissue. 
Key words: cartilage, insulin-like growth factor, leptin, osteoarthritis, synovial fluid 
Osteoarthritis (OA) is a common joint disease affecting mainly the hands, spine, 
hips, and knees. In OA a progressive loss of articular cartilage occurs which results in 
debilitating pain and disability (1 ). The etiology of OA is diverse with various 
predisposing factors rather than a single disease-causing entity (2). However, the 
distinguishing changes in cartilage leading to its degeneration are not well understood. 
One of the earliest events in OA is an increase in the water content of cartilage (3). This 
implies that there is a failure in the elastic restraint of the collagen network due to 
structural alterations (4), suggesting a shift in the cytokine/growth factor-controlled 
matrix homeostasis (5). This shift between synthesis and degradation ultimately favors 
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catabolic processes (5). 
One factor important in cartilage synthesis is insulin-like growth factor-I (IGF-I). This 
growth factor has been shown to stimulate the production of chondrocyte extracellular 
matrix components and the synthesis of collagen and proteoglycan (6-9). 
These anabolic effects help restore disrupted homeostasis even in the presence of 
the catabolic cytokines such as interleukin-lf3 (IL-1) and tumor necrosis factor-a. (TNF-
a.) (10,11). Although the levels ofIGF-I mRNA expression are high in (12) and in the 
synovial fluid (13) in OA, the arthritic chondrocytes appear non-responsive to the 
anabolic effects ofIGF-I (14). This lack ofresponsiveness may be explained by the 
increased presence of binding proteins in synovial fluid of the afflicted joints (13), thus 
limiting the availability ofIGF-I. 
In addition to IGF-I, other factors such as leptin may contribute to the 
maintenance of cartilage integrity (15,16). Recently, leptin receptors have been reported 
to be present in human chondrocytes (16) suggesting that cartilage is a leptin responsive 
tissue. In support of a role for leptin in cartilage, Fingenschau et al. have shown that 
chondrocytes stimulated with leptin have increased proteoglycan and collagen production 
(16). These observations served as a basis for examining the relationship between 
synovial fluid levels ofIGF-I and leptin in the present study. 
MATERIALS AND METHODS 
Subjects and tissue collection. The purpose of this study was to assess markers of 
cartilage metabolism in synovial fluid of osteoarthritic subjects and to make comparison 
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with those of non-osteoarthritic individuals. The study protocol and consent form were 
approved by the Institutional Review Board at Oklahoma State University. Synovial fluid 
specimens were obtained from a total of thirty-four individuals (21 females and 13 males) 
with and without OA (Table 1). Based on patient history, the incidence of knee OA in 
these individuals was unrelated to traumatic injury to the joints. Subjects were referred to 
the surgeon for the repair of their knees, and were otherwise considered healthy. On the 
day of surgery, synovial fluid was collected, aliquoted, and stored at -80°C for analyses. 
The joints of patients with insignificant levels of synovial fluid were irrigated with 1 to 2 
ml of normal saline and subsequent analyses were normalized to the synovial total 
protein concentration. Total protein concentrations in the synovial fluid were determined 
using reagents from Roche Diagnostics (Montclair, NJ) and analyzed by the Cobas-Fara 
II Clinical Analyzer. Synovial fluid values were corrected based on total protein levels. 
Synovial fluid insulin-like growth factor-I Synovial fluid IGF-I concentrations were 
determined using radioimmunoassay (RIA;.Diagnostic Systems Laboratory; Webster, 
TX) technique. Briefly, aliquoted synovial fluid samples were thawed and centrifuged at 
2400 x g for 2 min (17). A 100 µL aliquot of the specimen was added to a 
microcentrifuge tube for formic acid-acetone extraction in presence of 0.5% Tween 20. 
The extracted specimens were centrifuged and 50 µL of the supernatant were incubated 
in antibody-coated tubes in presence of 100 ul of [ 125I]-labeled IGF-I at room temperature 
following the manufacturer's protocol. The tubes were then decanted and counted in a 
gamma counter. The IGF-I concentrations in the synovial fluid specimens were 
determined using a log-logit curve. The curve was obtained using appropriate standards 
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and controls as provided by the manufacturer of the RIA kit. 
Synovial fluid IGFBP-3 Levels ofIGFBP-3 in synovial fluid were measured using RIA 
(Diagnostic Systems Laboratories; Webster, TX) technique. Briefly, aliquoted synovial 
fluid samples were thawed and centrifuged at 2400 x g for 2 min (17). A 100 µL aliquot 
of the specimen was added to a microcentrifuge tube and diluted 10-fold using a sample 
diluent as provided by the manufacturer. The diluted specimens were then incubated in 
antibody-coated tubes in presence of 100 ul of [1251]-labeled IGFBP-3 at room 
temperature overnight as recommended by the manufacturer. The tubes were then 
decanted and washed with 3 mL of deionized water. The washings were repeated 2 more 
times and the tubes were then counted in a gamma counter for 1 minute. The standards 
and controls provided by the manufacturer were used in plotting a log-logit curve. The 
IGFBP-3 concentrations in the synovial fluid specimens were multipled by the dilution 
factor and determining using the log-logit curve. 
Leptin concentrations in synovial fluid Synovial fluid leptin levels were measured 
using a non-competitive RIA (Diagnostic Systems Laboratory; Webster, TX) technique. 
Briefly, synovial fluid samples were thawed and centrifuged at 2400 x g for 2 min (17). A 
100 µL aliquot of the specimen was added to a microcentrifuge tube. The specimens were 
then incubated in antibody-coated tubes in presence of 100 ul of [1251]-labeled leptin at 
room temperature overnight as recommended by the manufacturer. The tubes were then 
decanted and washed with 3 mL of washing solution as provided in the kit. The washings 
were repeated 2 more times and the tubes were then counted in a gamma counter for 1 
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minute. Standards and controls provided by the manufacturer were used simultaneously 
to plot a log-logit curve. This curve was used to calculate the leptin concentrations in the 
syovial fluid specimens. 
Synovial fluid C-reactive protein (CRP) CRP in synovial fluid was measured using the 
Antibody Reagent Set II obtained from DiaSorin (Stillwater, MN). The test was 
performed using the Cobas-Fara II Clinical Analyzer (Montclair, NJ). Initially, a standard 
curve was determined using known amounts of CRP in lyophilized serum specimens. 
Briefly, antisera was added to aliquoted specimens of synovial fluid and incubated for 1 
minute. After which, the absorbance was measured and the CRP concentration was 
extrapolated from a standard curve. 
Statistical analysis Data analysis involved estimation of means, standard error of mean 
(SE), and analysis of variance using InStat Software (Version 3.0; San Diego, CA). 
When the analysis of variance indicated significant difference, the differences among 
means were investigated using the Tukey's multiple comparison procedure. P<0.05 was 
considered statistically significant. 
RESULTS 
In the present study, the amounts of synovial fluid specimens were limited. This 
restricted our ability to perform the validation tests for the concentrations of IGF-1, 
IGFBP-3, leptin, and CRP. Another limitation is that certain joints had to be lavaged by 
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using 1 to 2 mL of saline, therefore we could no longer assess these parameters per mL 
synovial fluid. That is the reason for reporting synovial fluid values of these markers per 
mg protein. This type of normalization has not been reported in the literature and the 
reproducibility of our data needs to be confirmed. Another point that should be 
mentioned is that there are currently no RIA kits specifically designed to assess the 
concentrations ofIGF-I, IGFBP-3, leptin, and CRP in the synovial fluid and hence the 
reliability, specificity, and validity of these RIA kits for use in synovial fluid need to be 
addressed. 
Results of the synovial fluid analyses are presented in Table 2. Synovial fluid 
specimens from female patients with OA had significantly higher concentrations ofIGF-
I, IGFBP-3, and leptin in comparison with females without OA. These significantly 
higher levels persisted even when values for IGF-I (Figure 1), IGFBP-3 (Figure 2), and 
leptin (Figure 3) were normalized to .total protein in the synovial fluid. 
In men, no statistically significant differences in synovial fluid IGF-I, IGFBP-3, and 
leptin (Table 2) or their protein-normalized concentrations (Figures 1, 2 and 3, 
respectively) were found in individuals with and without OA. 
Synovial fluid CRP and protein normalized CRP levels were not significantly 
different in OA afflicted individuals compared to individuals without OA in either gender 
(Table 2). 
DISCUSSION 
The balance between synthesis and degradation of cartilage matrix in joint tissue 
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is disrupted under pathological conditions such as ostearthritis, rheumatoid arthritis, and 
other related disorders (18, 19 ,20). Some of the most common characteristics of arthritic 
cartilage in the severe stages of the disease are decreased levels of macromolecules and 
increased degradative products. This study assessed the synovial fluid levels of IGF-I, 
IGFBP-3, and leptin in individuals with and without OA. 
Accumulating evidence suggests that IGF-I has an important role in maintaining 
one of the principal functions of cartilage cells and that is the production of the matrix 
proteoglycan molecules (10,21,22). In this study, synovial fluid levels ofIGF-I as 
expressed per mL were close to four-fold higher in women with OA compared to those 
without OA. The amount of synovial fluid surrounding the afflicted knee varies from one 
individual to the next. In some cases, to obtain synovial fluid samples from patients it is 
required that the joints be lavaged with saline resulting in the levels of solutes in these 
samples to become dilute. Therefore, expressing solute levels per mg total protein may 
adjust for this variability. In support of this notion, when IGF-I levels were expressed per 
mg protein, women with OA had around a two-fold increase in synovial fluid IGF-I only 
when compared to their normal counterparts. In either case, because IGF-I was higher in 
OA, it is expected that cartilage synthesis should prevail in women with OA. However, as 
our data and those of others indicate, levels ofIGF-binding proteins are also increased in 
OA (13,23). The bioavailability of the IGF-I is regulated by IGF-binding proteins, of 
which at least 6 different classes are known, with the most predominant binding protein 
being IGFBP-3 (24,25). In relation to the higher IGF-I, the levels of protein adjusted 
IGFBP-3 in synovial fluid were proportionately higher in women with OA compared to 
those without OA. This suggests that although IGF-I is more abundant in OA, it may not 
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be bioavailable to exert its beneficial effects on cartilage. Furthermore, increased local 
production ofIGFBP-3 has been suggested in inflamed joints (25). Thus, further limiting 
the action ofIGF-I during the progression of the disease (23). Development of treatment 
strategies that would either increase the levels ofbioavailable IGF-I and/or decrease the 
local production of IGF- binding proteins may be beneficial to restore homeostasis in 
OA. 
In addition to IGF-I, recent reports have suggested that the cytokine-like 
hormone, leptin, may play a role in cartilage (16). In order to examine whether synovial 
fluid levels ofleptin are affected in OA, we assessed synovial fluid leptin concentrations 
in individuals with and those without OA. Our results indicate that, at least in women and 
similar to IGF-I, both unadjusted as well as protein-normalized leptin levels are 
significantly higher in OA compared to normal. It is not clear whether the higher levels of 
leptin in synovial fluid are a result of increased local production of leptin or a reflection 
of higher circulating leptin levels. Higher circulating leptin levels have been reported in 
obesity (26,27,28) and being overweight is a predisposing factor in OA (29,30). 
Unfortunately, anthropometric data could not be obtained from individuals who 
participated in this study. Nonetheless, increased proteoglycan and collagen synthesis 
have been observed in in vitro studies where normal chondrocytes were stimulated with 
leptin (16). This suggests that leptin, similar to IGF-I, in the local environment of the 
chondrocyte stimulates cartilage repair. Whether leptin receptors are present in the 
cartilage of individuals with OA and whether these receptors are functional leading to 
higher levels of proteoglycan or collagen production need to be assessed in future studies. 
Synovial fluid levels ofIGF-I, IGFBP-3, and leptin were not different in men 
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whether with or without OA, indicating that these factors may not necessarily be involved 
in the pathophysiology of OA in men. However, since the men in this study may be at 
different stages of disease progression than the women, it is possible that the abundance 
and availability ofIGF-I may have been influenced by the stage of OA (31). In OA, as 
the repair process initially keeps pace with the progression of the disease, eventually it is 
superceded by the degenerative process leading to a more advanced stage of cartilage 
destruction (22,32). However, the stage of OA progression in our subject was not 
determined. Additionally, differences between genders in relation to OA have previously 
been described (33) including age of onset (34), hormonal effects (35,36), and underlying 
causes (37). Further examinations of synovial fluid as well as cartilage using screening 
tools for multiple factors such as microarray technology followed by more discriminating 
tools such as immunohistochemistry may provide basis for identification of 
distinguishing characteristics in men with OA versus those without OA. 
In summary, although the findings of the present study are of interest, these data 
should be considered preliminary and need to be confirmed in future studies. It would be 
meritorious to also assess these parameters in serum and investigate whether they 
correlate with synovial fluid levels. 
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Table I 
Description of study participants 
Gender Status of Knee Joint N= MeanAge±SE 
N-OA 7 39.7 ± 2.9 
Female 
OA 14 57.8 ± 5.5 
N-OA 9 42.7 ± 3.9 
Male 
OA 4 59.8 ± 10.5 
Non-Osteoarthritis (N-OA); Osteoarthritis (OA) 
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Table II 
Synovial fluid analysis from women and men with and without osteoarthritis 
Synovial Fluid F-NOA F-OA M-NOA M-OA 
Leptin (ng/mL) 7.89 ± 4.75 34.23 ± 5.54* 15.34 ± 4.12 23.95 ± 7.43 
IGF-1 (pg/mL) 13.2 ± 5.3 52.5 ± 14.2* 51.8 ± 8.8 66.9 ± 10.4 
IGFBP-3 (ng/mL) 5.0 ± 1.2 53.4 ± 4.0* 58.4 ± 16.9 74.6 ± 3.7 
C-Reactive Protein (CRP; µg/mL) 1.92 ± 0.65 3.62 ± 0.78 2.04 ± 0.32 3.12 ± 1.30 
Normalized CRP (µg/mg protein) 0.27 ± 0.07 0.27 ± 0.04 0.21 ± 0.05 0.20 ± 0.09 
Values are mean± SE; n = 4-14; * asterisk denotes values that are significantly different (P < 0.05) then the non-osteoarthritic 
counterpart. F-NOA (female non-osteoarthritis); F-OA (female osteoarthritis); M-NOA (male non-osteoarthritis); and M-OA (male 
osteoarthritis) 
Figure 1 
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M-NOA M-OA F-NOA F-OA 
Protein-normalized insulin-like growth factor-I (IGF-1) concentrations in synovial fluid 
of men and women with and without osteoarthritis. Bars represent mean+SE; n = 4-7 
samples per group. * Asterisk denotes that mean protein-normalized IGF-1 values in 
synovial fluid are significantly (P < 0.05) different in comparison to those of female 
without osteoarthritis. M, male; F, female; NOA, without osteoarthritis; OA, with 
osteoarthritis 
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Figure 2 
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Protein-normalized insulin-like growth factor binding protein-3 (IGFBP-3) 
concentrations in synovial fluid of men and women with and without osteoarthritis. Bars 
represent mean+SE; n = 4-9 samples per group. * Asterisk denotes that mean protein-
normalized IGFBP-3 values in synovial fluid are significantly (P < 0.05) different in 
comparison to those of female without osteoarthritis. M, male; F, female; NOA, 
individuals without osteoarthritis; OA, individuals with osteoarthritis 
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Figure 3 
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Protein-normalized leptin concentrations in synovial fluid of men and women with and 
without osteoarthritis. Bars represent mean+SE; n = 4-11 samples per group. * Asterisk 
denotes mean protein-normalized leptin values are significantly (P < 0.05) different in 
comparison to those of female without osteoarthritis. M, male; F, female; NOA, 
individuals without osteoarthritis; OA, individuals with osteoarthritis 
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CHAPTERV 
SUMMARY, CONCLUSIONS, IMPLICATIONS AND LIMITATIONS 
Smnmary 
The principal objective of this research was to elucidate if estrogen receptors 
(ERs) exist in human cartilage and whether their abundance varied between men and 
women with and without osteoarthritis (OA). Furthermore, this study was designed to 
investigate ifthere was a relationship between the abundance ofERs and higher 17P-
estradiol (E2) levels in the synovial fluid of individuals with OA in comparison to 
individuals without OA. This study also assessed the selective anabolic and catabolic 
markers of cartilage metabolism in the synovial fluid of individuals with and without OA. 
In Chapter I of this dissertation, three objectives are listed. Chapter III addressed 
objective 1 and 2, whereas Chapter IV addressed objective 3. The summary of outcomes 
for each objective will be presented and then general conclusions and recommendations 
for future research will be discussed. 
In Chapter III, amplification of cDNA from articular cartilage tissues using RT-
PCR showed the presence of mRNA for ERP and ERa. Furthermore, mRNA levels for 
ERP were greater in articular cartilage specimens obtained from women with 
osteoarthritic joints compared to specimens obtained from nonosteoarthritic joints. 
Western blot analysis confirmed the elevated protein levels of ERP but not ERa in 
women with OA in comparison to individuals without OA. The mRNA and protein levels 
for both ERa and ERP did not differ in men with or without OA. Positive nuclei 
immunostaining confirmed the presence of both ERa and ERP in the cartilage specimens 
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obtained from patients with OA. The mRNA levels of aromatase in articular cartilage of 
women with OA were found to be higher than those of women without OA. No 
difference between aromatase mRNA levels was observed among men. 
In regards to objective 2, synovial fluid specimens from female patients with OA 
had significantly (P<0.03) higher concentrations ofE2 in comparison with those ofnon-
osteoarthritic females or males with or without OA. However, there were no statistically 
significant differences in E2 levels of synovial fluid between men with or without OA. 
In Chapter 3, synovial fluid specimens from female patients with OA had 
significantly higher concentrations of insulin-like growth factor-I (IGF-I), IGF binding 
protein-3 (IGFBP-3), and leptin (P < 0.05, 0.001, 0.01, respectively) in comparison with 
females without OA. These significantly higher levels persisted even when values for 
IGF-I, IGFBP-3, and leptin (P < 0.05, 0.05, 0.05, respectively) were normalized to total 
protein in the synovial fluid. In men, no statistically significant differences in synovial 
fluid IGF-I, IGFBP-3, and leptin or their protein-normalized concentrations were found 
in individuals with and without OA. Synovial fluid C-reactive protein (CRP) and protein 
normalized CRP levels were not significantly different in OA afflicted individuals 
compared to individuals without OA in either gender. 
Conclusions 
The findings of this study suggest the presence of both ERa and ERP in articular 
cartilage with greater abundance of ERP compared to ERa, indicating that ERs may have 
a functional role in cartilage metabolism. These findings suggest that there may be a 
cause and effect relationship that exists between the incidence of OA and the increased 
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presence of the ER~ sub-type in cartilage. It is possible that this is analogous to the 
presence ofERa in mammary tissues and its connection with breast cancer. However, 
this is speculative and further investigation is needed to confirm whether such a 
relationship exists. 
In the present study, synovial fluid concentrations of E2 were significantly greater in 
women with OA as compared to those without OA or men with or without OA. Hence, 
higher levels of estrogen in synovial fluid may play a role in the etiology of OA in 
women but not in men. Whether a similiar relationship exists in men with respect to 
androgen concentrations has to be investigated. The higher E2 concentrations. in synovial 
fluid of women with OA leads us to speculate that localized E2 in the synovial cavity may 
be involved in the degenerative process of cartilage. At this time, the pathophysiology of 
estrogen accumulation in the synovial fluid of osteoarthritic joints is not clear. Since 
higher expression of mRNA for aromatase was detected only in women with OA, this 
may partly explain the increased concentration of E2 in synovial fluid of these women. 
Accumulating evidence suggests that IGF-I has an important role in maintaining one 
. of the principal functions of cartilage cells, which is the production of the matrix 
proteoglycan molecules. This study assessed the synovial fluid levels of IGF-1, IGFBP-3, 
and leptin in individuals with and without OA. Synovial fluid levels ofIGF-I as expressed 
per mL were close to four-fold higher in women with OA compared to those without OA. 
The amount of synovial fluid surrounding the afflicted knee varies among individuals and 
hence this variation affects the levels of solutes present in the specimens. Therefore, by 
expressing solute levels per mg total protein the variability can be adjusted. In support of this 
statement, whenIGF-I levels were expressed per mg protein, women with OA had around a 
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two-fold increase in synovial fluid IGF-I only when compared to their normal counterparts. 
In either case, because IGF-I was higher in OA, it is expected that cartilage synthesis should 
prevail in women with OA. However, as our data and those of others indicate, levels ofIGF-
binding proteins are also increased in OA. The bioavailability of the IGF-I is regulated by 
IGF-binding proteins, of which at least 6 different classes are known, with the most 
predominant binding protein being IGFBP-3. In relation to the higher IGF-I, the levels of 
protein adjusted IGFBP-3 in synovial fluid were proportionately higher in women with OA 
compared to those without OA. This suggests that although IGF-I is more abundant in the 
synovial fluid of patients with OA, it may not be bioavailable to exert its beneficial effects 
on cartilage. Development of treatment strategies that would either increase the levels of 
bioavailable IGF-I and/or decrease the local production of IGF-binding proteins may be 
beneficial to restore homeostasis in OA. 
In addition to the anabolic effect ofIGF-I on cartilage, recent reports have 
suggested that the cytokine-like hormone, leptin,. may play a role in cartilage metabolism. 
In order to examine whether synovial fluid levels of leptin are affected in OA, we 
assessed synovial fluid leptin concentrations in individuals with and those without OA. 
Our results indicated that in synovial fluid of women, similar to changes in IGF-I, both 
unadjusted as well as normalized leptin levels were significantly higher in individuals 
with OA. It is not clear whether this higher level ofleptin in synovial fluid is a result of 
increased local production of leptin or a reflection of higher circulating leptin levels. 
Higher circulating leptin levels have been reported in obesity and being overweight is a 
predisposing factor in OA. Nonetheless, increased proteoglycan and collagen synthesis 
have been observed in in vitro studies where normal chondrocytes were stimulated with 
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leptin. This observation suggests that leptin, similar to IGF-I, in the local environment of 
the chondrocytes stimulates cartilage repair. Whether leptin receptors are present in the 
cartilage of individuals with OA need to be assessed in future studies. 
Synovial fluid levels of either IGF-I and IGFBP-3, or leptin were not different in 
men irrespective of their disease status, indicating that these factors may not necessarily 
be involved in the pathophysiology of OA in men. 
Implications 
The findings of this study, at least, in the case of women with knee OA, suggest 
that women may benefit from compounds that can compete for estrogen receptors and 
perhaps neutralize the deleterious effects of estrogen on cartilage tissue. Therefore, 
women with OA may benefit from agents such as selective estrogen receptor modulators 
(SERMs) that can compete with estrogens in occupying ERs, particularly ERB present in 
the knee cartilage. SERMs are defined as a group of compounds behaving as estrogen 
agonists in certain tissues while acting as antagonists in some other tissues. To this date, 
ERB has been found in certain tissues including brain, bone, bladder, and vascular 
epithelial which are responsive to estrogen as well as SERMs. Recent investigations on 
the effects of synthetic and naturally occurring SERMs on various tissues suggest that 
these diverse molecules may influence target tissues by exerting their effects mainly 
through ERB. The tissue distribution of these two ERs differs which may explain the 
agonistic or antiagonistic properties of SERMs in various tissues. Therefore, cells that 
preferentially express ERB including chondrocytes, as observed in this study, are more 
likely to respond to SERMs. However, this concept is speculative and requires further 
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investigation. The impact of naturally occurring SERMs such as genistein and daizein 
and synthetic SERMs such as ipriflavone and raloxifene on improvement of OA 
conditions remains to be shown. 
Whether the increased levels oflGF-1 and leptin in the synovial fluid of women with OA 
are due to lack of their diffusion and uptake by cartilage tissue remain to be illustrated. 
Similar implications may exist in male OA, however, because of the small sample size 
used in this study no conclusions can be made regarding the role of these anabolic 
factors. Future studies are needed to explore the pathophysiological pathways which may 
cause degeneration of cartilage resulting in OA in men and women and to identify 
whether there are gender differences. 
Limitations 
In this study, as with any study utilizing fresh operating room specimens the 
amounts of cartilage and synovial fluid specimens were limited to the samples made 
available by the orthopedic surgeon. Because the amount of articular cartilage and 
synovial fluid specimens varied from one subject to the next, it limited our ability to 
perform the proposed analyses. In order to address the issue of variations in the amount 
of synovial fluid samples, the orthopedic surgeon lavaged the joint with 1 to 2 mL saline 
to flush the contents of the joint. Hence, reporting the values of the measured markers 
based on volume, though reported in the literature, was not appropriate. For these 
reasons, we had to normalize the concentrations of E2, IGF-1, IGFBP-3, CRP, and leptin 
in the synovial fluid to total protein concentration. This type of normalization has never 
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been done in other laboratories, hence it would be necessary to validate our findings in 
future studies. Furthermore, the isolation of RNA from articular cartilage was very 
difficult due to its rubbery texture which further limited the number of assays that we 
could run which in certain cases reduced the sample size and statistical power of the 
study. 
Another point that should be emphasized is that there are currently no RIA kits 
specifically designed to assess the concentrations ofE2, IGF-1, IGFBP-3, CRP, and leptin 
in the synovial fluid. We use kits manufactured for serum analyses which utilized 
controls and standards provided by the manufacturers. In spite of using serum kits for 
synovial fluid, the analyses that were performed produced values and curves that were 
comparable to the manufacturer's recommended levels. Future studies should address the 
reliability, specificity, and validity of these kits for use in synovial fluid. Unfortunately, 
we were unable to address these issues in our study due to the small amounts of synovial 
fluid available. Furthermore, we were unable to look at parallelism or recovery from 
analyses where the specimens were initially extracted and then diluted to measure the 
markers such as IGF-1 and IGFBP-3. Due to our limited sample size and volume, we 
were unable to calculate the inter- and intra- assay variability. Therefore, these issues 
have to be addressed in future studies. 
Due to our limitations in the present study, it would be necessary to confirm the 
findings of this study using a much larger sample size. This larger sample size and tissue 
availability will allow us to pool specimens within the same gender and joint status group 
and will provide us with adequate RNA samples for more quantitative analysis of gene 
expression using Northern blot and Real-Time PCR. With a larger sample size, it would 
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also make it possible to perform more in-depth immuncytochemistry analysis of the 
estrogen receptors as well as analysis of other cartilage markers. If a larger pool of 
subjects were available for studying changes in synovial fluid in OA, it would be feasible 
to perform validation studies for the immunoassay kits that are designed to be used for 
serum analyses. 
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APPENDIXC 
Oklahoma State University 
Consent for Participation in a Research Study Entitled 
The role of estrogen and estrogen receptors in knee osteoarthritis 
I, state that I am years of age and agree to 
participate in research study being conducted by Bahram H. Arjmandi, PhD and Mark E. 
Munson, M.D. I understand that while the study will be under the supervision of these 
individuals, the other professionals who work with them may assist or act on their behalves. 
Purpose of the Study 
The purpose of this study is to examine the relationship between the occurrence of knee 
osteoarthritis and estrogen levels (a female sex hormone which is also present in males as well 
but in much lower concentrations) in synovial fluid and the presence of estrogen receptors 
(estrogen exerts its effect on a tissue through these molecules) in the cartilage. Furthermore, we 
will investigate the role of other molecules that may function importantly in maintaining the 
normal physiology and integrity of the articular. In this proposed research, knee cartilage and 
synovial fluid from both men and women of comparable age with and without knee OA will be 
obtained. 
Procedure 
I understand that the following procedures will be performed: 
1. I will have about 1 to 4 ml synovial fluid aspirated from knee joint by Dr. Munson during 
the surgery. 
2. The cartilage tissue specimen that is removed during the procedure will be collected by 
trained personnel and stored appropriately for the experiments proposed by the 
investigators 
Potential Risks 
Removal of synovial fluid from my knee may cause slight discomfort. 
Potential Benefits 
I will receive information on my cartilage status. 
Alternatives to Participation 
Although my participation in this study would help the healthcare providers to better understand 
the causes of the disorder, however, the outcome of my surgical treatment is not altered by my 
lack of participation in this study. 
Research/Treatment Cost 
I understand that I will not have to pay for the cost of the laboratory work directly associated with 
this study. 
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Compensation of Injury 
I understand that the research procedures are independent of my surgical procedures. My cartilage 
tissue and synovial fluid will be examined after the surgery. I understand that the surgeon will 
not remove additional cartilage for this research. 
Confidentiality of Data 
I hereby agree to allow my name and medical records to be made available to Drs. 
Bahram H. Arjmandi, and Mark E Munson involved in the study for the purpose of evaluating the 
results of this study. I consent to the publication of any data which may result from this 
investigation, providing that neither my name nor any other identifying information is used in 
conjunction with such publication. Precautions to maintain confidentiality of my medical records 
will be taken. 
Right to Withdraw 
I have been advised by Dr.Munson that I am not obligated to participation in this study. 
Right of Refusal 
I have been advised that Drs. Arjmandi and Munson will answer any questions that I may have 
regarding this research study and that I am free to withdraw my consent and discontinue 
participation at any time without penalty. 
I also understand that the investigators have the right to withdraw me from the study at any time. 
I acknowledge that has explained to me the risks involved, 
the need for the research, and has offered to answer any questions which I may have concerning 
the procedures to be followed. I freely and voluntarily consent to participate in this study. I 
understand that I may keep a copy of this consent form for my own information. 
Signatures 
Volunteer (sign and date) 
Investigator ( sign and date) 
Witness of Volunteer's 
Signature (sign and date) 
(Print name) 
(Print name) 
(Print name) 
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University, Stillwater, OK 
1996-97:Member, Graduate Student Committee in Human Nutrition and Dietetics; 
University of Illinois at Chicago, Chicago, IL 
TEACHING EXPERIENCE 
2000-02:Guest Lecturer, Nutrition and Aging (NSCI 5393) Department of Nutritional 
Sciences, College of Human Environmental Sciences; Oklahoma State University, 
Stillwater, OK 
2000-01:Teaching Assistant, Introductory Nutrition (NSCI 2114) Department of 
Nutritional Sciences, College of Human Environmental Sciences; Oklahoma State 
University, Stillwater, OK 
1999:Guest Lecturer, New Findings in Nutrition (NSCI 5230) Department of Nutritional 
Sciences, College of Human Environmental Sciences; Oklahoma State University, 
Stillwater, OK 
1996:Guest Lecturer, Science of Food (HND 300) Department of Human Nutrition and 
Dietetics, College of Associated Health Professions, University of Illinois at Chicago, IL 
1996:Guest Lecturer, Clinical Nutrition 11-Gastroenterology (HND 420) Department of 
Human Nutrition and Dietetics, College of Associated Health Professions, University of 
Illinois at Chicago, IL 
19.95-97:Teaching Assistant, Science of Food (HND 300), Department of Human 
Nutrition and Dietetics, College of Associated Health Professions, University of Illinois 
at Chicago, IL 
